Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             752 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Author index 2009
15 S2 p. S201-S214
14 p.
artikel
2 Editorial Board 2009
15 S2 p. iii-
1 p.
artikel
3 O.023 Advances in basal ganglia functional organization Obeso, J.
2009
15 S2 p. S7-
1 p.
artikel
4 O.040 Advances in Friedreich's ataxia Cooper, J.
2009
15 S2 p. S11-
1 p.
artikel
5 O.024 Advances in the medical treatment of Parkinson's disease Chana, P.
2009
15 S2 p. S7-
1 p.
artikel
6 O.031 Allied health interventions for movement disorders Bloem, B.
2009
15 S2 p. S9-
1 p.
artikel
7 O.059 Are growth factors the answer in Parkinson's disease? Barker, R.
2009
15 S2 p. S15-S16
2 p.
artikel
8 O.091 Are there useful animal models of parkinsonism? Schallert, T.
2009
15 S2 p. S24-
1 p.
artikel
9 O.075 Atypical parkinsonism Lang, A.E.
2009
15 S2 p. S19-
1 p.
artikel
10 O.054 Cardiovascular dysfunction in Parkinson disease Kaufmann, H.
2009
15 S2 p. S14-
1 p.
artikel
11 O.061 Choreas - phenomenology and differential diagnosis Walker, R.H.
2009
15 S2 p. S16-
1 p.
artikel
12 O.104 Cognitive dysfunction/dementia Kulisevsky, J.
2009
15 S2 p. S27-
1 p.
artikel
13 O.008 Cognitive functions in the STN (insight from intracerebral recordings) Rektor, I.
2009
15 S2 p. S3-
1 p.
artikel
14 O.003 Community-based rehabilitation: from neurons to neighborhoods Hirsch, M.
2009
15 S2 p. S2-
1 p.
artikel
15 O.038 Continuous dopaminergic stimulation (CDS) Ray Chaudhuri, K.
2009
15 S2 p. S11-
1 p.
artikel
16 O.093 Control of microglial motility by purinergic receptors Traynelis, S.
2009
15 S2 p. S24-S25
2 p.
artikel
17 O.084 Correlation of the genetics, symptomatology, pathology and stem cell proliferation in Huntington's disease Faull, R.
2009
15 S2 p. S22-
1 p.
artikel
18 O.073 Current understanding of myoclonus Caviness, J.
2009
15 S2 p. S19-
1 p.
artikel
19 O.074 Current understanding of myoclonus Hallett, M.
2009
15 S2 p. S19-
1 p.
artikel
20 O.027 Dealing with the devil in the detail - some thoughts about the next model of the basal ganglia Arbuthnott, G.
2009
15 S2 p. S8-
1 p.
artikel
21 O.067 Diagnosing pre-motor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging Berendse, H.W.
2009
15 S2 p. S18-
1 p.
artikel
22 O.060 Did levodopa versus dopamine agonists trials teach us when and how to start symptomatic therapy? Waters, C.
2009
15 S2 p. S16-
1 p.
artikel
23 O.039 Drug induced movement disorders Tarsy, D.
2009
15 S2 p. S11-
1 p.
artikel
24 O.072 Dystonia Schneider, S.
2009
15 S2 p. S19-
1 p.
artikel
25 O.047 Dystonia: a surgeon's point of view Aziz, T.
2009
15 S2 p. S13-
1 p.
artikel
26 O.010 Emergencies in PD Pal, P.
2009
15 S2 p. S3-S4
2 p.
artikel
27 O.009 Emergencies in PD (acute dyskinesia, PD and general surgery, pulmonary dysfunction) Onofrj, M.
2009
15 S2 p. S3-
1 p.
artikel
28 O.095 Epidemiologic studies of anti-inflammatories in Parkinson's disease Manthripragada, A. Wahner
2009
15 S2 p. S25-
1 p.
artikel
29 O.006 Epidemiology of dystonia Goldman, S.
2009
15 S2 p. S2-S3
2 p.
artikel
30 O.098 Epidemiology of Parkinson's disease and related disorders – studies in special populations Tanner, C.M.
2009
15 S2 p. S26-
1 p.
artikel
31 O.068 Evaluation of strategies for pre-motor detection of Parkinson's disease Siderowf, A.
2009
15 S2 p. S18-
1 p.
artikel
32 O.019 Exercise programs improve mobility and balance in people with Parkinson's disease Gobbi, L.
2009
15 S2 p. S6-
1 p.
artikel
33 O.102 Factores genéticos en la etiología de la enfermedad de Parkinson [Genetic factors in the etiology of Parkinson's disease] Gershanik, O.
2009
15 S2 p. S27-
1 p.
artikel
34 O.097 Findings from prospective cohorts - disease risk factors Ascherio, A.
2009
15 S2 p. S25-S26
2 p.
artikel
35 O.041 From bench to bedside: new treatments for Friedreich's ataxia Pandolfo, M.
2009
15 S2 p. S11-
1 p.
artikel
36 O.049 Functional and structural imaging of cognitive deflcits in PD Rektorova, I.
2009
15 S2 p. S13-
1 p.
artikel
37 O.078 Future therapies for Parkinson's disease Rascol, O.
2009
15 S2 p. S20-
1 p.
artikel
38 O.056 Gastrointestinal dysfunction in Parkinson's disease Pfeiffer, R.
2009
15 S2 p. S15-
1 p.
artikel
39 O.036 Gaucher's disease and Parkinson's disease Wood, N.
2009
15 S2 p. S10-
1 p.
artikel
40 O.092 Genetic and sporadic ataxias Schöls, L.
2009
15 S2 p. S24-
1 p.
artikel
41 O.083 HD pathogenesis and experimental therapeutics: lessons for PD Ross, C.A.
2009
15 S2 p. S21-S22
2 p.
artikel
42 O.044 How do we slow progression of Parkinson's disease Kieburtz, K.
2009
15 S2 p. S12-
1 p.
artikel
43 O.085 Huntington disease (HD): clinical features and experimental therapeutics Shoulson, I.
2009
15 S2 p. S22-
1 p.
artikel
44 O.013 Imaging non-motor symptoms of PD Stoessl, A.J.
2009
15 S2 p. S5-
1 p.
artikel
45 O.079 Impulse control disorders in Parkinson's disease: prevalence and possible risk factors Weintraub, D.
2009
15 S2 p. S20-S21
2 p.
artikel
46 O.032 Intensive voice treatment for Parkinson disease (LSVT LOUD): a neuroplasticity principled approach supported by technology Ramig, L.
2009
15 S2 p. S9-
1 p.
artikel
47 O.063 Involvement of canonical and non-canonical D1 signaling pathways in L-dopa-induced dyskinesia Bezard, E.
2009
15 S2 p. S16-S17
2 p.
artikel
48 O.052 Iron as a cause of Parkinson disease - a myth or a well established hypothesis? Friedman, A.
2009
15 S2 p. S14-
1 p.
artikel
49 O.051 Iron transport in Parkinson's disease Hirsch, E.
2009
15 S2 p. S14-
1 p.
artikel
50 O.105 Is alpha-synuclein pathology propagated from one neuron to another in Parkinson's disease? Brundin, P.
2009
15 S2 p. S27-S28
2 p.
artikel
51 O.089 Is genetic testing for parkinsonism useful? Klein, C.
2009
15 S2 p. S23-S24
2 p.
artikel
52 O.066 Is the loss of thalamostriatal neurons protective in parkinsonism? Kusnoor, S.
2009
15 S2 p. S17-
1 p.
artikel
53 O.020 Is there a pathogenic role for mitochondria in PD? Przedborski, S.
2009
15 S2 p. S6-
1 p.
artikel
54 O.080 Leucine-rich repeat kinase 2: animal models Farrer, M.
2009
15 S2 p. S21-
1 p.
artikel
55 O.099 Low frequency stimulation of PPTg in PD: minor beneflts on gait, peculiar changes of cortical metabolism and cognitive performance Stefani, A.
2009
15 S2 p. S26-
1 p.
artikel
56 O.082 LRRK2 parkinsonism Wszolek, Z.
2009
15 S2 p. S21-
1 p.
artikel
57 O.050 Management of dementia in Parkinson's disease Burn, D.
2009
15 S2 p. S13-S14
2 p.
artikel
58 O.045 Mechanisms of dystonia Standaert, D.
2009
15 S2 p. S12-
1 p.
artikel
59 O.076 Medical management of early Parkinson's disease Hauser, R.
2009
15 S2 p. S20-
1 p.
artikel
60 O.026 Mice over-expressing wild-type human alpha-synuclein as tools for therapeutic discovery in Parkinson's disease Chesselet, M.-F.
2009
15 S2 p. S8-
1 p.
artikel
61 O.048 Mild cognitive impairment in patients with Parkinson's disease Adler, C.H.
2009
15 S2 p. S13-
1 p.
artikel
62 O.018 Mobility and exercise in movement disorders Giladi, N.
2009
15 S2 p. S6-
1 p.
artikel
63 O.090 Modeling sporadic Parkinson's disease by selective gene manipulation Mandel, S.
2009
15 S2 p. S24-
1 p.
artikel
64 O.033 Motor learning in Parkinson's disease: limitations and potential Nieuwboer, A.
2009
15 S2 p. S10-
1 p.
artikel
65 O.071 Movement disorders: PET Brooks, D.
2009
15 S2 p. S18-S19
2 p.
artikel
66 O.035 Movement disorders with systemic metabolic involvement Gershanik, O.
2009
15 S2 p. S10-
1 p.
artikel
67 O.069 Neuroimaging in Parkinson's disease Eidelberg, D.
2009
15 S2 p. S18-
1 p.
artikel
68 O.094 Neuroinflammation in the living brain of Parkinson's disease Ouchi, Y.
2009
15 S2 p. S25-
1 p.
artikel
69 O.014 Neuropathology of non-motor features of Parkinson disease Dickson, D.W.
2009
15 S2 p. S5-
1 p.
artikel
70 O.100 New targets for DBS: can DBS modulate non-motor symptoms? Moro, E.
2009
15 S2 p. S26-
1 p.
artikel
71 O.012 Non-motor extranigral signs and symptoms in Parkinson's disease Wolters, E.C.
2009
15 S2 p. S4-
1 p.
artikel
72 O.001 Parkinson's disease and issues related to driving Uitti, R.J.
2009
15 S2 p. S1-
1 p.
artikel
73 O.037 Parkinson's disease in sub-Saharan Africa Guttman, M.
2009
15 S2 p. S10-S11
2 p.
artikel
74 O.103 PET assessment of neurodegeneration in Parkinson's disease de la Fuente-Fernandez, R.
2009
15 S2 p. S27-
1 p.
artikel
75 O.002 Piloting the NPF data-driven quality initiative to improve Parkinson's disease management Siderowf, A.
2009
15 S2 p. S1-
1 p.
artikel
76 O.062 Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to dyskinesia Cenci, M.A.
2009
15 S2 p. S16-
1 p.
artikel
77 O.106 Post-mortem analyses of fetal transplants of dopamine neurons in Parkinson's disease patients reveal no or minimal pathology Isacson, O.
2009
15 S2 p. S28-
1 p.
artikel
78 O.005 Practical strategies for sexual interventions in Parkinson's disease Bronner, G.
2009
15 S2 p. S2-
1 p.
artikel
79 O.011 Psychogenic movement disorders Jankovic, J.
2009
15 S2 p. S4-
1 p.
artikel
80 O.053 Quantitative estimation of regional brain iron with MRI Martin, W.R.W.
2009
15 S2 p. S14-
1 p.
artikel
81 O.101 Rationale for targeting the thalamic centre median–parafascicular complex in the surgical treatment of Parkinson's disease Kerkerian-Le Goff, L.
2009
15 S2 p. S26-S27
2 p.
artikel
82 O.016 REM sleep behavior disorder: can you predict Parkinson's in your dreams? Postuma, R.
2009
15 S2 p. S5-
1 p.
artikel
83 O.007 Risk factors for primary late-onset dystonia Defazio, G.
2009
15 S2 p. S3-
1 p.
artikel
84 O.029 Scales and measurement of dysfunction in Parkinson's disease: depression and anxiety Marsh, L.
2009
15 S2 p. S9-
1 p.
artikel
85 O.030 Scales to evaluate psychosis in Parkinson's disease Goetz, C.G.
2009
15 S2 p. S9-
1 p.
artikel
86 O.015 Sleepiness in Parkinson's disease Arnulf, I.
2009
15 S2 p. S5-
1 p.
artikel
87 O.025 Stem cell therapy in Parkinson's disease Hoffer, B.
2009
15 S2 p. S8-
1 p.
artikel
88 O.064 Thalamic changes in Parkinson's disease Halliday, G.
2009
15 S2 p. S17-
1 p.
artikel
89 O.055 The autonomic nervous system and sleep disorders in Parkinson's disease Ray Chaudhuri, K.
2009
15 S2 p. S14-S15
2 p.
artikel
90 O.021 The MitoPark mouse - using mouse genetics to impair DA neuron mitochondria Ekstrand, M.I.
2009
15 S2 p. S7-
1 p.
artikel
91 O.070 The placebo-reward hypothesis: dopamine and the placebo effect de la Fuente-Fernandez, R.
2009
15 S2 p. S18-
1 p.
artikel
92 O.022 Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease Beal, M.F.
2009
15 S2 p. S7-
1 p.
artikel
93 O.081 The role of LRRK2 in the etio-pathogenesis of Parkinson's disease Bonifati, V.
2009
15 S2 p. S21-
1 p.
artikel
94 O.028 The spectrum of clinical manifestations of basal ganglia disorders: a challenge for any new model Obeso, J.
2009
15 S2 p. S8-
1 p.
artikel
95 O.087 Treatment of dementia and depression in Parkinson's disease Reichmann, H.
2009
15 S2 p. S22-S23
2 p.
artikel
96 O.086 Treatment of dysautonomia associated with Parkinson's disease Jankovic, J.
2009
15 S2 p. S22-
1 p.
artikel
97 O.077 Treatment of non-motor symptoms of PD Pahwa, R.
2009
15 S2 p. S20-
1 p.
artikel
98 O.088 Treatment of sleep disorders in PD Oertel, W.
2009
15 S2 p. S23-
1 p.
artikel
99 O.046 Treatments of dystonia: the neurologist's point of view Vidailhet, M.
2009
15 S2 p. S12-S13
2 p.
artikel
100 O.017 Triggering endogenous neuroprotective processes through exercise in models of dopamine deflciency Zigmond, M.J.
2009
15 S2 p. S5-S6
2 p.
artikel
101 O.042 Ultrasound in sialorrhea treatment in Parkinson's patients Truong, D.
2009
15 S2 p. S12-
1 p.
artikel
102 O.065 Ultrastructural plasticity of corticostriatal and thalamostriatal glutamatergic synapses in Parkinson's disease Smith, Y.
2009
15 S2 p. S17-
1 p.
artikel
103 O.096 Use of neuropathological lesions as endpoints in movement disorder epidemiology Ross, W.
2009
15 S2 p. S25-
1 p.
artikel
104 O.043 Use of sonography in PD and related disorders – applications and perspectives Berg, D.
2009
15 S2 p. S12-
1 p.
artikel
105 O.004 Who cares for the caregiver? Dyck, C.
2009
15 S2 p. S2-
1 p.
artikel
106 O.107 Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression Hong, J.-S.
2009
15 S2 p. S28-
1 p.
artikel
107 O.057 Will continuous dopaminergic stimulation prevent motor complications? Stocchi, F.
2009
15 S2 p. S15-
1 p.
artikel
108 O.058 Will continuous dopamine stimulation prevent motor complications? Antonini, A.
2009
15 S2 p. S15-
1 p.
artikel
109 O.034 Wilson's disease Gouider-Khouja, N.
2009
15 S2 p. S10-
1 p.
artikel
110 P2.213 Ab amyloid deposits are common in brains of non-demented PD patients Gomperts, S.
2009
15 S2 p. S147-
1 p.
artikel
111 P3.131 Abnormal cerebellar activity in Parkinson's disease – a network perturbation approach McKeown, M.J.
2009
15 S2 p. S181-S182
2 p.
artikel
112 P1.205 A case of chorea as the initial manifestation of SLE triggered by estrogen Sung, Y.-H.
2009
15 S2 p. S81-
1 p.
artikel
113 P1.159 A clinical study of pain symptoms in Moldavian Parkinson disease patients Pavlic, G.
2009
15 S2 p. S69-S70
2 p.
artikel
114 P2.070 Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia Bishnoi, M.
2009
15 S2 p. S107-
1 p.
artikel
115 P2.037 Activation of the subthalamic nucleus during emotional processing predicts severity of postoperative depressive symptoms in PD-patients Übl, J.H.
2009
15 S2 p. S98-
1 p.
artikel
116 P1.164 Activity of daily life in patients with early vs late onset of Parkinson's disease Shyndryaeva, N.
2009
15 S2 p. S71-
1 p.
artikel
117 P3.144 Acute L-DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of Parkinsonian rats Szkilnik, R.
2009
15 S2 p. S185-
1 p.
artikel
118 P2.173 Adjunctive ropinirole prolonged-release has similar effects on motor and non-motor symptoms in PD compared with carbidopa–levodopa, but delays dyskinesia onset Watts, R.L.
2009
15 S2 p. S137-
1 p.
artikel
119 P2.052 Adverse events stimulation related and surgical complications in 62 patients treated with STN DBS for Parkinson disease: long term follow-up Sarubbo, S.
2009
15 S2 p. S102-
1 p.
artikel
120 P3.042 A GATA-2-switch model of a-synuclein overexpression in sporadic Parkinson's disease Liao, Z.
2009
15 S2 p. S159-
1 p.
artikel
121 P3.009 Aging and neurodegeneration: common targets, common hopes Outeiro, T.
2009
15 S2 p. S150-
1 p.
artikel
122 P3.156 Alcohol dehydrogenase 2 polymorphism is not associated to the risk for essential tremor Martinez-Oliva, C.
2009
15 S2 p. S188-
1 p.
artikel
123 P2.118 Allosteric modulation of group III metabotropic glutamate receptor 4: a potential neuroprotective approach for the treatment of Parkinson's disease Betts, M.
2009
15 S2 p. S121-
1 p.
artikel
124 P3.117 Alpha-synuclein-directed alterations in membrane electrophysiological properties: potential role for alpha-synuclein pores in cell death Feng, L.R.
2009
15 S2 p. S178-
1 p.
artikel
125 P3.132 Alpha-synuclein in stem cells Mochizuki, H.
2009
15 S2 p. S182-
1 p.
artikel
126 P3.011 Alpha-synuclein phosphorylation mediated by iron and rotenone in a cellular model of Parkinson's disease Perfeito, R.
2009
15 S2 p. S150-
1 p.
artikel
127 P3.010 Altered mitochondrial functions by alpha-synuclein overexpression and aggregation in human neuroblastoma cells Parihar, M.
2009
15 S2 p. S150-
1 p.
artikel
128 P2.004 Amygdala stimulation is not able to rescues the long-term potentiation (LTP) at the depotentiation synapses in the dentate gyrus Duany, C.
2009
15 S2 p. S89-
1 p.
artikel
129 P2.025 Amyotrophic lateral sclerosis and Hirayama disease-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy Kumar, A.
2009
15 S2 p. S94-S95
2 p.
artikel
130 P1.111 Analysis of serum anti-thyroid antibody titers in Parkinson's disease and multiple system atrophy Lee, W.Y.
2009
15 S2 p. S57-
1 p.
artikel
131 P3.159 Analysis of surgical intrathecal [i.t.] baclofen [ITB] implant results emphasizing revision surgery in a mixed pediatric/adult population Awaad, Y.
2009
15 S2 p. S189-
1 p.
artikel
132 P3.028 Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson's disease patients Duque Rodríguez, A.F.
2009
15 S2 p. S155-
1 p.
artikel
133 P3.140 An analysis of the relationship shared by environmental toxin exposure and movement disorders Seibert, P.
2009
15 S2 p. S184-
1 p.
artikel
134 P2.058 Anatomical localization of active contacts of deep brain electrodes – technical note Urgosik, D.
2009
15 S2 p. S104-
1 p.
artikel
135 P3.137 A new high throughput PC-aided super-microisland method for primary dopaminergic neurons Porokuokka, L.L.
2009
15 S2 p. S183-
1 p.
artikel
136 P3.154 A novel protection by Rg1 on MPP+ induced iron accumulation by ROS and nuclear factor-kappaB signal pathway Xu, H.M.
2009
15 S2 p. S187-S188
2 p.
artikel
137 P2.151 Anticholinergics for axial symptoms in Parkinson's disease with subthalamic nucleus stimulation Onozawa, R.
2009
15 S2 p. S130-
1 p.
artikel
138 P2.111 Anti-dyskinetic effects of flibanserin on levodopa-induced dyskinesia in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease Gerlach, M.
2009
15 S2 p. S119-
1 p.
artikel
139 P2.103 Antidyskinetic effects of levetiracetam on levodopa-induced dyskinesias in Parkinson's disease: a randomised, double-blind, placebo-controlled trial Löhle, M.
2009
15 S2 p. S116-S117
2 p.
artikel
140 P1.192 Anti-glutamic acid decarboxylase antibodies: a Brazilian neurological series Teive, H.
2009
15 S2 p. S78-
1 p.
artikel
141 P1.029 Apathy may be a predictive factor of dementia in Parkinson's disease Dujardin, K.
2009
15 S2 p. S36-
1 p.
artikel
142 P1.073 A pharmacoeconomic evaluation of botulinum toxin A therapy in the Philippines Colacion, J.
2009
15 S2 p. S47-
1 p.
artikel
143 P2.205 A phase I/II clinical trial to evaluate the safety and efflcacy of ProSavin®, a gene therapy approach for Parkinson's disease Jarraya, B.
2009
15 S2 p. S145-
1 p.
artikel
144 P3.033 Apolipoprotein E alleles in Greek patients with Parkinson's disease. Association with the presence of dementia and hallucinations Karakasis, C.
2009
15 S2 p. S156-
1 p.
artikel
145 P3.115 A possible correlation between memory and neuronal oxidative stress status in a 6-OHDA model of Parkinson's disease Ciobica, A.
2009
15 S2 p. S177-S178
2 p.
artikel
146 P2.090 A preliminary pharmacokinetic study comparing L-Dopa and Duodopa in adult rats Papathanou, M.
2009
15 S2 p. S113-
1 p.
artikel
147 P1.010 A proactive approach to falls in Parkinson's disease Grantier, L.L.
2009
15 S2 p. S31-
1 p.
artikel
148 P1.042 A prospective study of mood states in Parkinson's disease (PROMS-PD) Brown, R.
2009
15 S2 p. S39-S40
2 p.
artikel
149 P3.167 Aquatic physical therapy approach, using principles of Halliwick Concept, for improvement of aquatic motor skills, among Parkinson's disease patients Loureiro, A.P.C.
2009
15 S2 p. S191-
1 p.
artikel
150 P2.142 A randomized, controlled trial of twice daily pramipexole in early PD Kieburtz, K.
2009
15 S2 p. S128-
1 p.
artikel
151 P2.092 A randomized, double-blind evaluation of levodopa/carbidopa/entacapone versus immediate-release levodopa/carbidopa in patients with Parkinson's disease exhibiting nonmotor symptoms of wearing off Stacy, M.
2009
15 S2 p. S113-S114
2 p.
artikel
152 P2.204 A randomized, double-blind, placebo-controlled, delayed start study to assess safty, tolerability and efflcacy of green tea polyphenols in Parkinson's disease Chan, P.
2009
15 S2 p. S145-
1 p.
artikel
153 P2.097 A reactive nitrogen species scavenger is neuroprotective in multiple Parkinson's disease animal models Hung, L.
2009
15 S2 p. S115-
1 p.
artikel
154 P1.082 A retrospective assessment of physical, cognitive, and affective factors that relate to falls in individuals with Parkinson's disease Masterson, M.
2009
15 S2 p. S50-
1 p.
artikel
155 P1.216 Arytenoid tremor predicts severity of glottic stenosis in multiple system atrophy Ozawa, T.
2009
15 S2 p. S84-S85
2 p.
artikel
156 P3.015 Assessing non-cortical glucose metabolism in corticobasal syndrome Claassen, D.
2009
15 S2 p. S151-S152
2 p.
artikel
157 P3.166 Assessment of Awareness of Disability (AAD) – a case study of its clinical utility in advanced Parkinson's disease (PD) patient Jansa, J.
2009
15 S2 p. S190-S191
2 p.
artikel
158 P2.106 Assessment of symptomatic and neuroprotective efflcacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease Pinna, A.
2009
15 S2 p. S117-
1 p.
artikel
159 P2.179 Assessment of the Alzheimer Carer Quality of Life Instrument (ACQLI) among Swedish Alzheimer's and Parkinson's disease carers Hagell, P.
2009
15 S2 p. S138-
1 p.
artikel
160 P2.021 Astrocytes: central role in Parkinson's pathology? Schmidt, S.
2009
15 S2 p. S93-S94
2 p.
artikel
161 P1.174 A successful computer method for assessing drawing impairment in Parkinson's disease Westin, J.
2009
15 S2 p. S73-S74
2 p.
artikel
162 P1.090 Attention network in AD and DLB patients: a resting fMRI study Franciotti, R.
2009
15 S2 p. S52-
1 p.
artikel
163 P3.112 Autoimmune parkinsonism Caramelli, A.
2009
15 S2 p. S177-
1 p.
artikel
164 P1.135 Automated Parkinson's disease motor assessment for clinical and ambulatory monitoring Heldman, D.
2009
15 S2 p. S63-
1 p.
artikel
165 P2.065 Automatic classiflcation of 18FDG-PET scans in parkinsonism Garraux, G.
2009
15 S2 p. S106-
1 p.
artikel
166 P1.170 Autonomic cardiovascular disfunction in early Parkinson's disease Strano, S.
2009
15 S2 p. S72-S73
2 p.
artikel
167 P3.096 Axial and PRE-camptocormic forms in LRRK2 mutation Parkinson's disease. Review of surgical results Echebarria Mendieta, S.G.
2009
15 S2 p. S173-
1 p.
artikel
168 P1.161 Axial symptoms and basal ganglia in Parkinson's disease. Does side matter? Sarwar, A.
2009
15 S2 p. S70-
1 p.
artikel
169 P3.049 b2 Adrenergic receptor activation induces microglial NADPH oxidase activation and dopaminergic neurotoxicity through an ERK-dependent/protein kinase A-independent pathway Qian, L.
2009
15 S2 p. S161-
1 p.
artikel
170 P1.107 Balance and eye movement training to improve gait in people with progressive supranuclear palsy Al Faqih, S.
2009
15 S2 p. S56-
1 p.
artikel
171 P3.068 Basal ganglia hyperindirect pathway: direct projections from the subthalamic nucleus innervating the ventral motor thalamic nuclei in MPTP-treated primates Rico, A.
2009
15 S2 p. S166-
1 p.
artikel
172 P1.184 Behavioral disturbances in Parkinson's disease: a study from Slovak movement disorders center Martinková, J.
2009
15 S2 p. S76-
1 p.
artikel
173 P2.017 Behavioural and biochemical characterization of c-Rel mutant mice as model of Parkinson's disease Pinna, A.
2009
15 S2 p. S92-
1 p.
artikel
174 P2.022 Behavioural improvements of hemiparkinsonian rats after intrastriatal injection of botulinum toxin A Wree, A.
2009
15 S2 p. S94-
1 p.
artikel
175 P2.049 Beneflts and risks of deep brain stimulation (DBS) for Parkinson's disease (PD) – results from the PD SURG study Rick, C.
2009
15 S2 p. S101-
1 p.
artikel
176 P2.041 Beyond motor control: does deep brain stimulation of the subthalamic nucleus alter reward processing in patients with Parkinson's disease? Lueken, U.
2009
15 S2 p. S99-
1 p.
artikel
177 P3.045 Bilateral ballism after herpes encephalitis with thalamic lesion Baik, J.S.
2009
15 S2 p. S159-S160
2 p.
artikel
178 P2.044 Bilateral GPi DBS for OFF dystonias and ON dyskinesias in juvenile PD Mari, Z.
2009
15 S2 p. S100-
1 p.
artikel
179 P2.042 Bilateral malfunction of cerebral electrodes at generalized dystonia patient Mandat, T.
2009
15 S2 p. S99-
1 p.
artikel
180 P2.148 Bilateral STN DBS improves manual performance time in Parkinson's disease Llumiguano, C.
2009
15 S2 p. S129-
1 p.
artikel
181 P2.143 Bilateral subthalamic deep brain stimulation in Parkinson disease patients with severe tremor Kim, H.-J.
2009
15 S2 p. S128-
1 p.
artikel
182 P2.198 Bilateral thalamic deep brain stimulation for orthostatic tremor Lyons, M.
2009
15 S2 p. S143-
1 p.
artikel
183 P2.112 Bioactivity of CERE-120 (AAV2-neurturin gene therapy) in advanced Parkinson's disease (PD): post-mortem analysis of two autopsy cases Bartus, R.T.
2009
15 S2 p. S119-
1 p.
artikel
184 P1.150 Body mass index, abdominal circumference and the risk of falls in Parkinson's disease Munhoz, R.P.
2009
15 S2 p. S67-
1 p.
artikel
185 P3.195 Borna disease virus phosphoprotein interferences with the brain monoaminergic system via promoting tyrosine hydroxylase expression in neuronal cells Jian-ping, Y.
2009
15 S2 p. S198-
1 p.
artikel
186 P2.115 Botulinum toxin B vs. botulinum toxin A for the treatment of sialorrhea in Parkinson's disease and amyotrophic lateral sclerosis Ash, R.
2009
15 S2 p. S120-
1 p.
artikel
187 P1.071 Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy Teive, H.
2009
15 S2 p. S47-
1 p.
artikel
188 P1.097 Brain functional correlates of geriatric assessment in dementia with Lewy bodies Perneczky, R.
2009
15 S2 p. S53-S54
2 p.
artikel
189 P1.113 Brain monoamine systems in multiple system atrophy: a positron emission tomography study Pavese, N.
2009
15 S2 p. S58-
1 p.
artikel
190 P3.051 Calcium channel blockers can minimize iron-induced apoptosis in neural stem cells Chen, W.-X.
2009
15 S2 p. S161-
1 p.
artikel
191 P2.207 Canada's head-to-head exercise rehabilitation challenge for Parkinson's disease: a systematic comparison of the most effective strategies for symptom improvement Almeida, Q.J.
2009
15 S2 p. S146-
1 p.
artikel
192 P2.033 Can daily programming and acute inpatient rehabilitation “fast-track” symptomatic recovery after DBS surgery for Parkinson's disease? Frisina, P.
2009
15 S2 p. S97-
1 p.
artikel
193 P2.032 Capability of identifying red nuclei in different pulse sequences of regular 1.5 T magnetic resonance images Chiou, S.-M.
2009
15 S2 p. S97-
1 p.
artikel
194 P3.087 Carbon monoxide poisoning induced nigrostriatal dopaminergic dysfunction detected using Positron Emission Tomography (PET) Rissanen, E.
2009
15 S2 p. S170-S171
2 p.
artikel
195 P2.069 Cardiovascular dysautonomia: the link between heart transplant patients and Parkinson's disease Post, K.K.
2009
15 S2 p. S107-
1 p.
artikel
196 P1.182 Caregiver burden in apathy and impulsivity in Parkinson's disease Leroi, I.
2009
15 S2 p. S75-S76
2 p.
artikel
197 P1.169 Cases of Parkinson's disease and movement disorders in Gobi-Altai province last 5 years Urtnasan, B.
2009
15 S2 p. S72-
1 p.
artikel
198 P1.186 Case study: pychogenic movement disorder response to psychotherapeutic interventions Barton, K.
2009
15 S2 p. S76-S77
2 p.
artikel
199 P3.179 Case study use of near-infrared light to reduce symptoms associated with restless legs syndrome Mitchell, U.
2009
15 S2 p. S194-
1 p.
artikel
200 P1.019 Catamenial and oral contraceptive-induced exacerbation of chorea in chorea-acanthocytosis: case report Munhoz, R.P.
2009
15 S2 p. S33-S34
2 p.
artikel
201 P1.115 Central conduction deflcits assessments before and after repetitive transcranial stimulation: a multiple system atrophy case of parkinsonism type Wang, H.
2009
15 S2 p. S58-
1 p.
artikel
202 P2.064 Centropontine myelinolysis and hypokalemia Ben Hamouda, I.
2009
15 S2 p. S106-
1 p.
artikel
203 P1.122 Cerebral hemodynamic dysfunction in parkinsonian patients Štenc Bradvica, I.
2009
15 S2 p. S60-
1 p.
artikel
204 P1.227 Cerebral infratentorial large B-cell lymphoma presenting as parkinsonism Lin, C.
2009
15 S2 p. S87-
1 p.
artikel
205 P3.058 Ceruloplasmin is involved in the nigral iron accumulation of 6-OHDA lesioned rats Wang, J.
2009
15 S2 p. S163-
1 p.
artikel
206 P1.065 Cervical dystonia: clinical and therapeutic features in 85 patients Munhoz, R.P.
2009
15 S2 p. S45-
1 p.
artikel
207 P2.152 Changes in early-morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system: two large, placebo-controlled trials Pahwa, R.
2009
15 S2 p. S130-S131
2 p.
artikel
208 P2.124 Changes in quality of life and nocturnal symptoms in sleep-impaired patients with advanced Parkinson's disease treated with ropinirole prolonged release Martinez-Martin, P.
2009
15 S2 p. S123-
1 p.
artikel
209 P1.202 Changes of procedural learning in patients with Wilson disease Wang, X.-P.
2009
15 S2 p. S81-
1 p.
artikel
210 P1.044 Characteristics of depression in Parkinson disease Kasten, M.
2009
15 S2 p. S40-
1 p.
artikel
211 P3.119 Characteristics of resting-state oscillatory activity in the basal ganglia-cortical loop in the 6-OHDA-lesioned rat models of Parkinson's disease Li, M.
2009
15 S2 p. S178-S179
2 p.
artikel
212 P1.007 Charcot's contribution to the study of Tourette's syndrome Teive, H.
2009
15 S2 p. S30-
1 p.
artikel
213 P2.162 Chewing gum signiflcantly improves swallow frequency and latency in patients with Parkinson's disease South, A.
2009
15 S2 p. S133-S134
2 p.
artikel
214 P2.074 Class speciflc manifestation in drug induced parkinsonism Munhoz, R.P.
2009
15 S2 p. S108-
1 p.
artikel
215 P3.201 Clinical and electrophysiological correlations in different types of paroxysms in sleep Rukhadze, I.
2009
15 S2 p. S199-
1 p.
artikel
216 P3.146 Clinical and MRI correlations in Parkinson's disease patients with headache Verulashvili, I.
2009
15 S2 p. S185-S186
2 p.
artikel
217 P1.033 Clinical correlates of brain SPECT perfusion in Parkinson disease dementia Kramberger, M.G.
2009
15 S2 p. S37-
1 p.
artikel
218 P1.109 Clinical features of atypical Parkinsonian disorders Chen, L.
2009
15 S2 p. S57-
1 p.
artikel
219 P1.196 Clinical proflle of community-based and hospital-based essential tremor in Nigerians Bankole, I.
2009
15 S2 p. S79-
1 p.
artikel
220 P3.026 Clinico-pathologic comparison of Perry syndrome and distal spinal and bulbar muscular atrophy Lash, J.
2009
15 S2 p. S154-S155
2 p.
artikel
221 P2.081 Clozapine exerts neuroprotection via reducing microglia-mediated inflammation Zhou, H.
2009
15 S2 p. S110-
1 p.
artikel
222 P2.200 Cognitive deflcits in drug induced parkinsonism Kim, J.-S.
2009
15 S2 p. S144-
1 p.
artikel
223 P1.022 Cognitive dysfunction in apathy and impulsivity in Parkinson's disease Andrews, M.
2009
15 S2 p. S34-
1 p.
artikel
224 P3.016 Cognitive features are more predictive of corticobasal degeneration (CBD) pathology than motor features in corticobasal syndrome Kranick, S.
2009
15 S2 p. S152-
1 p.
artikel
225 P1.123 Cognitive function in Parkinson's disease patients with Dopamine Dysregulation syndrome Caravona, N.
2009
15 S2 p. S60-
1 p.
artikel
226 P1.026 Cognitive proflle and mild cognitive impairment (MCI) in Parkinson's disease: baseline data from the PROMS-PD cohort Whitehead, D.
2009
15 S2 p. S35-
1 p.
artikel
227 P1.099 Color discrimination impairment with patients with Parkinson's disease and their regional cerebral blood flow changes Watanabe, M.
2009
15 S2 p. S54-
1 p.
artikel
228 P2.195 Color vision and Parkinson's disease; comparison with essential tremor and controls Kim, J.-S.
2009
15 S2 p. S142-
1 p.
artikel
229 P1.204 Combined resting–postural tremor – a variant of essential tremor Ahlskog, M.C.
2009
15 S2 p. S81-
1 p.
artikel
230 P3.148 Common genetic variants at the 5′ end of vitamin D receptor (VDR) gene are associated with Parkinson disease (PD) susceptibility Butler, M.W.
2009
15 S2 p. S186-
1 p.
artikel
231 P3.160 Communication circles – a cost effective model of on-going speech therapy for individuals with Parkinson's disease Bereskin, B.
2009
15 S2 p. S189-
1 p.
artikel
232 P1.145 Community-administered care for PD patients in XiangFan, Hubei, China Luo, Y.
2009
15 S2 p. S66-
1 p.
artikel
233 P3.136 Comorbid vascular diseases in patients with Parkinson disease and Parkinsonian syndrome – preliminary results Norman, R.A.
2009
15 S2 p. S183-
1 p.
artikel
234 P2.136 Comparative efflcacy and safety of a novel carbidopa–levodopa product (IPX066) and Sinemet in advanced Parkinson's disease Ellenbogen, A.
2009
15 S2 p. S126-
1 p.
artikel
235 P1.068 Comparative study of the botulinum toxin type A potency between Botox® and BTXA®: using human extensor brevis muscle Park, M.
2009
15 S2 p. S46-
1 p.
artikel
236 P2.060 Comparison of efflcacy and side effects observed using peroperative and postoperative STN macrostimulation in Parkinson's disease: does both testing match? Xie, J.
2009
15 S2 p. S104-S105
2 p.
artikel
237 P1.155 Computerized cognitive testing in idiopathic PD with motor fluctuations: patient experiences Pandey, S.
2009
15 S2 p. S68-S69
2 p.
artikel
238 P2.182 Coping and quality of life in Parkinson disease: the deep brain stimulation effect Montel, S.
2009
15 S2 p. S139-
1 p.
artikel
239 P2.183 Coping and quality of life in Parkinson's disease Montel, S.
2009
15 S2 p. S139-
1 p.
artikel
240 P1.138 Coping in Parkinson's disease: an examination of the coping inventory for stressful situations Hurt, C.
2009
15 S2 p. S64-
1 p.
artikel
241 P2.180 Coping style and quality of life in persons with Parkinson's disease Kerckhofs, E.
2009
15 S2 p. S138-S139
2 p.
artikel
242 P2.030 Cortical effects correlate with the outcome of deep brain stimulation in the rat subthalamic nucleus Arbuthnott, G.
2009
15 S2 p. S96-
1 p.
artikel
243 P2.001 Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervations Ansah, T.
2009
15 S2 p. S88-
1 p.
artikel
244 P2.168 Cost-effectiveness of rasagiline compared to other flrst line treatment options of early Parkinson's disease in the United States Farkouh, R.
2009
15 S2 p. S135-
1 p.
artikel
245 P3.082 Covalent modiflcation of superoxide dismutase 2 by dopamine oxidation products Belluzzi, E.
2009
15 S2 p. S169-
1 p.
artikel
246 P3.012 CSF from Parkinson disease patients differentially affects a-synuclein density and cell growth of microglia compared to astrocytes Schiess, M.
2009
15 S2 p. S151-
1 p.
artikel
247 P2.091 D1 antagonist blocks L-DOPA-induced striatal and nigral ERK1/2 phosphorylation in a rat model of Parkinson's disease Sivam, S.
2009
15 S2 p. S113-
1 p.
artikel
248 P2.005 Decreased motor coordination in the rat model of Parkinson's disease (PD) after 20 weeks of lesion Gambhir, H.
2009
15 S2 p. S89-
1 p.
artikel
249 P1.217 Decreased putamen aldehyde dehydrogenase in Parkinson disease Goldstein, D.
2009
15 S2 p. S85-
1 p.
artikel
250 P2.035 Deep brain stimulation effects on orthostatic regulations in patients with Parkinson's disease Hou, J.G.
2009
15 S2 p. S97-S98
2 p.
artikel
251 P2.031 Deep brain stimulation in Parkinson's disease – evaluation of functional cortical perfusion in a non-motor area Azevedo, E.
2009
15 S2 p. S96-
1 p.
artikel
252 P1.004 Deep brain stimulation of CM-SPv-Voi complex for alleviating symptoms of Tourette syndrome Janik, P.
2009
15 S2 p. S30-
1 p.
artikel
253 P2.043 Deep brain stimulation of globus pallidus versus subthalamic nucleus for alleviating of dystonia symptoms among NBIA patients Mandat, T.
2009
15 S2 p. S99-S100
2 p.
artikel
254 P2.055 Deep brain stimulation outcomes for Parkinson's disease and essential tremor Seibert, P.
2009
15 S2 p. S103-
1 p.
artikel
255 P3.080 Deep brain stimulation regulates peripheral glucose metabolism in humans: from Parkinson to diabetes Rieu, I.
2009
15 S2 p. S169-
1 p.
artikel
256 P1.175 Deflning a test score for status assessment during motor fluctuations in Parkinson's disease Westin, J.
2009
15 S2 p. S74-
1 p.
artikel
257 P1.031 Dementia may not be inevitable in Parkinson's disease: memory and cognitive impairment in an elderly cohort Fendrich, M.
2009
15 S2 p. S36-S37
2 p.
artikel
258 P1.213 Demonstration of F-18 FDG-PET protocol for imaging neuronal activation: human motor cortex activation using F-18 FDG-PET Kim, S.
2009
15 S2 p. S83-S84
2 p.
artikel
259 P3.106 Dendritic cell vaccine against human a-synuclein aggregates Cao, C.
2009
15 S2 p. S175-
1 p.
artikel
260 P1.046 Depression in Parkinson's disease patients: the role of the clinical nurse specialist to improve the quality of life Lachance, L.
2009
15 S2 p. S40-S41
2 p.
artikel
261 P3.186 Depressive symptoms and nucturnal disturbances in Bosnia-Herzegovina patients with Parkinsons's disease Sinanovic, O.
2009
15 S2 p. S196-
1 p.
artikel
262 P2.023 Detection of a-synuclein oligomers in CSF from Parkinson's disease patients Tokuda, T.
2009
15 S2 p. S94-
1 p.
artikel
263 P1.190 Detection of Lewy body disease in patients with late-onset depression, anxiety and psychotic disorder with myocardial meta-iodobenzylguanidine scintigraphy Kobayashi, K.
2009
15 S2 p. S78-
1 p.
artikel
264 P1.030 Detection of Parkinson's disease dementia in routine practice Dujardin, K.
2009
15 S2 p. S36-
1 p.
artikel
265 P1.139 Determinants of quality of life in Parkinson disease Kertelge, L.
2009
15 S2 p. S64-
1 p.
artikel
266 P1.126 Developing a risk model for Parkinson disease Chung, R.-H.
2009
15 S2 p. S61-
1 p.
artikel
267 P1.023 Development of task switching and error monitoring in children Gupta, R.
2009
15 S2 p. S34-S35
2 p.
artikel
268 P1.036 Diagnosis of dementia in Parkinson's disease: a retrospective and a validation study in the clinical practice Vanacore, N.
2009
15 S2 p. S38-
1 p.
artikel
269 P2.186 Dietary characteristics of Chinese PD patients: food intake survey results Tan, X.
2009
15 S2 p. S140-
1 p.
artikel
270 P3.032 Differences in gene expression patterns in the olfactory bulb of Parkinson patients and related disorders? Ingrassia, A.
2009
15 S2 p. S156-
1 p.
artikel
271 P1.140 Differences in myocardial sympathetic degeneration and the clinical features of subtypes of Parkinson's disease Kim, S.J.
2009
15 S2 p. S64-S65
2 p.
artikel
272 P1.144 Different effects between acupuncture and anti-parkinsonian medicine on the cortical excitability in patients with Parkinson's disease Lin, Y.C.
2009
15 S2 p. S65-S66
2 p.
artikel
273 P1.151 Differential diagnoses of 1528 patients with parkinsonism followed in a tertiary movement disorders clinic Munhoz, R.P.
2009
15 S2 p. S67-S68
2 p.
artikel
274 P3.061 Differential distribution of tyrosine hydroxylase isoforms in the human brain Shehadeh, J.
2009
15 S2 p. S164-
1 p.
artikel
275 P1.077 Differential effects of dopamine replacement on clinical and laboratory measures of postural control in persons with Parkinson disease Foreman, K.
2009
15 S2 p. S48-
1 p.
artikel
276 P2.134 Differential response of bradykinesia and hypokinesia to levodopa in Parkinson's disease Espay, A.
2009
15 S2 p. S126-
1 p.
artikel
277 P3.114 Different types of alpha-synuclein are degraded by autophagic pathway Kangyong, L.
2009
15 S2 p. S177-
1 p.
artikel
278 P1.221 Diffusion tensor imaging of the substantia nigra on 3 Tesla MRI: comparison of Parkinson's disease with age matched controls Kumari, R.
2009
15 S2 p. S86-
1 p.
artikel
279 P2.080 Dimebon™ is neuroprotective in a model of Parkinson's disease Staal, R.G.W.
2009
15 S2 p. S110-
1 p.
artikel
280 P1.101 Do DAT scans change patient management? Yarwood, N.
2009
15 S2 p. S55-
1 p.
artikel
281 P2.095 Do dopaminergic drugs induce a place preference in normal rat? Zengin, Y.
2009
15 S2 p. S114-
1 p.
artikel
282 P3.178 Does quetiapine improve REM sleep behavior disorder (RBD) in Parkinson's disease? 3 case reports Carvalho, D.
2009
15 S2 p. S194-
1 p.
artikel
283 P2.045 Dopamine dysregulation syndrome (DDS): worse after bilateral STN DBS? Mari, Z.
2009
15 S2 p. S100-
1 p.
artikel
284 P3.083 Dopamine oxidation products as mitochondrial endotoxins, a potential molecular mechanism for selective neurodegeneration in Parkinson disease Arduini, I.
2009
15 S2 p. S169-S170
2 p.
artikel
285 P2.019 Dopamine transporter knock-down in mice results in loss of nigral dopaminergic neurons and alters the effects of pesticide exposure Richter, F.
2009
15 S2 p. S93-
1 p.
artikel
286 P2.050 Do pre-existing psychiatric disorders affect quality of life following deep brain stimulation for Parkinson's disease? Robottom, B.
2009
15 S2 p. S101-S102
2 p.
artikel
287 P2.165 Dose-related decrease in “off” time with ropinirole prolonged release in patients with advanced Parkinson's disease Stocchi, F.
2009
15 S2 p. S134-S135
2 p.
artikel
288 P1.001 Double-blind controlled randomized study of the use of levetiracetam to treat tics in children and adolescents with Tourette syndrome Awaad, Y.
2009
15 S2 p. S29-
1 p.
artikel
289 P2.158 Duodenal levodopa infusion improves motor symptoms and quality of life in advanced Parkinson disease: report of nine patients Santos-García, D.
2009
15 S2 p. S132-
1 p.
artikel
290 P2.128 Duodopa therapy in patients with advanced Parkinson's disease Kramberger, M.G.
2009
15 S2 p. S124-
1 p.
artikel
291 P3.078 Dynamics of electrical activity of the caudate nucleus in the sleep–wakefulness cycle Oniani, T.
2009
15 S2 p. S168-
1 p.
artikel
292 P1.039 Ecologically triggered premature ageing and dementia and other famous neuropsychiatric features were described by largely forgotten pellagrologists 200 years ago Williams, A.C.
2009
15 S2 p. S39-
1 p.
artikel
293 P1.028 EEG dominant alpha frequency variability forecasts the appearance of fluctuating cognition in PDD patients Bonanni, L.
2009
15 S2 p. S36-
1 p.
artikel
294 P1.054 Effectiveness of learning based training memory and sensorimotor training for patients with focal hand dystonia McKenzie, A.
2009
15 S2 p. S42-S43
2 p.
artikel
295 P2.011 Effect of aging on SNpc neuron loss, striatal dopamine and genea expression in C57BL/6 and Swiss-Webster mice following MPTP administration Jiao, Y.
2009
15 S2 p. S91-
1 p.
artikel
296 P3.192 Effect of bilateral globus pallidus internus deep brain stimulation on periodic limb movements in Parkinson's disease patient and possible mechanism Lyons, M.
2009
15 S2 p. S197-
1 p.
artikel
297 P1.053 Effect of botulinum toxin type A in retrocollis patients Banach, M.
2009
15 S2 p. S42-
1 p.
artikel
298 P2.144 Effect of combined application of quercetin and desferrioxamine on mitochondrial antioxidants, nucleic acids and neurotransmitters in 6-hydroxydopamine-induced neurotoxicity in aged rats Kumar, P.
2009
15 S2 p. S128-
1 p.
artikel
299 P2.038 Effect of electrode implantation to STN on motor system in Parkinson's disease: a fMRI study Jech, R.
2009
15 S2 p. S98-
1 p.
artikel
300 P1.148 Effect of Parkinson's disease on adaptation-learning in a 3D virtual reality environment Mongeon, D.
2009
15 S2 p. S67-
1 p.
artikel
301 P3.161 Effect of physical rehabilitation on perceived quality of life of persons with Parkinson disease Dobi, D.
2009
15 S2 p. S189-
1 p.
artikel
302 P3.054 Effect of prenatal manganese intoxication on dopaminergic neurotranssmision in the brain of rats lesioned as neonates with 6-hydroxydopamine Nowak, P.
2009
15 S2 p. S162-
1 p.
artikel
303 P2.170 Effect of rotigotine on control of early morning motor function and sleep quality in subjects with idiopathic Parkinson's disease Trenkwalder, C.
2009
15 S2 p. S136-
1 p.
artikel
304 P3.182 Effect of tetrabenazine use in restless legs syndrome Jia, J.
2009
15 S2 p. S195-
1 p.
artikel
305 P2.177 Effects of a multi-mode exercise program on quality of life and overall physical activity level in people with Parkinson's disease Gobbi, R.
2009
15 S2 p. S138-
1 p.
artikel
306 P1.081 Effects of auditory, attentional, and combined cueing strategies on gait during single and dual cognitive tasks in Parkinson's disease Lohnes, C.A.
2009
15 S2 p. S49-S50
2 p.
artikel
307 P1.100 Effects of dopaminergic treatment on putaminal dopamine turnover measured with Wolz, M.
2009
15 S2 p. S54-S55
2 p.
artikel
308 P1.047 Effects of green tea on haloperidol-induced anxiety, tardive dyskinesia and central serotonin dopamine metabolism: a model study Malik, T.
2009
15 S2 p. S41-
1 p.
artikel
309 P1.225 Effects of home exercise on the risk of falls and their influence on quality of life Maki, T.
2009
15 S2 p. S87-
1 p.
artikel
310 P1.224 Effects of home exercises in patients with Parkinson's disease Maki, T.
2009
15 S2 p. S87-
1 p.
artikel
311 P1.075 Effects of non-contact boxing training on spatiotemporal gait parameters in persons with Parkinson's disease: a case series Combs, S.
2009
15 S2 p. S48-
1 p.
artikel
312 P2.104 Effects of pardoprunox (SLV308), a partial D2/D3 receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity Bétry, C.
2009
15 S2 p. S117-
1 p.
artikel
313 P2.012 Effects of Parkinson's disease rat induction on skeletal muscle morphology Loureiro, A.P.C.
2009
15 S2 p. S91-
1 p.
artikel
314 P2.203 Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson's disease. Questionnaire and polysomnography study Dusek, P.
2009
15 S2 p. S145-
1 p.
artikel
315 P2.094 Effects of several dopamine agonists on 6-hydroxydopamine-induced ER stress in the mouse brain Tanaka, K.-I.
2009
15 S2 p. S114-
1 p.
artikel
316 P3.074 Effects of stimulation of the basolateral amygdala on the acquisition of a motor skill in rats hemiparkisonizadas Carrero, Y.
2009
15 S2 p. S167-
1 p.
artikel
317 P2.059 Effects of subthalamic nucleus lesions and short-term stimulation upon striatal glutamate levels in awake intact and 6-hydroxy/dopamine-lesioned rats Walker, R.
2009
15 S2 p. S104-
1 p.
artikel
318 P2.191 Effects of the treatment scheme factor on behavioral sensitization induced by the repeated administration of ethanol Araujo, N.
2009
15 S2 p. S141-S142
2 p.
artikel
319 P3.197 Effects of the treatment scheme factor on blood ethanol levels of mice repeatedly treated with ethanol Araujo, N.
2009
15 S2 p. S198-
1 p.
artikel
320 P1.008 Effects on cognition in patients with intractable obsessive-compulsive disorder by neurosurgery of double frontier limb lesions in internal capsule Wang, X.-P.
2009
15 S2 p. S31-
1 p.
artikel
321 P2.159 Efflcacy and safety of once-daily (qd) pramipexole extended-release for advanced Parkinson's disease Schapira, A.
2009
15 S2 p. S133-
1 p.
artikel
322 P2.101 Efflcacy and safety of preladenant, a novel A2A receptor antagonist, as a levodopa adjunct in patients with moderate-to-severe Parkinson's disease Hauser, R.A.
2009
15 S2 p. S116-
1 p.
artikel
323 P2.086 Efflcacy and tolerability of prolonged-release Ropinirole (Requip XL) in the elderly with Parkinson's disease Isaacson, S.
2009
15 S2 p. S112-
1 p.
artikel
324 P2.149 Efflcacy of apomorphine infusion on mood and depression aspects of non-motor symptoms in advanced Parkinson's disease Naidu, Y.
2009
15 S2 p. S130-
1 p.
artikel
325 P2.089 Efflcacy of pramipexole extended release (ER) and switching from pramipexole immediate release (IR) to ER in Japanese advanced PD patients Mizuno, Y.
2009
15 S2 p. S112-S113
2 p.
artikel
326 P2.206 EIF4G1 mutations in familial parkinsonism Chartier-Harlin, M.-C.
2009
15 S2 p. S145-S146
2 p.
artikel
327 P1.129 End of life in Parkinson's disease Feve, A.
2009
15 S2 p. S62-
1 p.
artikel
328 P3.157 Endoplasmic reticulum stress induced hyperphosphorylation of tau by activating GSK-3β Zhengqi, F.
2009
15 S2 p. S188-
1 p.
artikel
329 P2.121 Enhancing safe mobility in patients with Parkinson's disease: effect of dual task training during aerobic and moderate exercise Byl, N.
2009
15 S2 p. S122-
1 p.
artikel
330 P2.013 Enriched environment partially reverses dopamine cell loss following MPTP in mice Sashkin, N.
2009
15 S2 p. S91-
1 p.
artikel
331 P2.197 Essential tremor and spasmodic dysphonia response to bilateral thalamic deep brain stimulation: review of experience and possible mechanism Lyons, M.
2009
15 S2 p. S143-
1 p.
artikel
332 P3.027 Estrogen related genes and Parkinson's disease Chung, S.J.
2009
15 S2 p. S155-
1 p.
artikel
333 P2.110 Evidence for association of high-dose levodopa therapy with intellectual and psychiatric complications of Parkinson's disease Hamza, T.
2009
15 S2 p. S119-
1 p.
artikel
334 P1.168 Evolution of incident Parkinson disease, the flrst year of motor symptoms Tveiten, O.
2009
15 S2 p. S72-
1 p.
artikel
335 P1.171 Evolving non-motor symptoms in Parkinson disease patients. A cross-sectional study Vela, L.
2009
15 S2 p. S73-
1 p.
artikel
336 P1.040 Executive and memory decline in a longitudinally followed group of non-demented patients with idiopathic Parkinson's disease Zhelev, Y.
2009
15 S2 p. S39-
1 p.
artikel
337 P1.067 Executive dysfunction in hemifacial spasm Ochudlo, S.
2009
15 S2 p. S46-
1 p.
artikel
338 P1.021 Executive functions in a virtual world: a study in Parkinson's disease Albani, G.
2009
15 S2 p. S34-
1 p.
artikel
339 P2.096 Exendin-4 potentiates L-DOPA-evoked DA release in rat striatum Abuirmeileh, A.
2009
15 S2 p. S114-S115
2 p.
artikel
340 P2.154 Exendin-4 promotes recovery of both behavioral and neurochemical deflcits in a “pre-motor” rodent model of Parkinson's disease Rampersaud, N.
2009
15 S2 p. S131-
1 p.
artikel
341 P1.088 Experiences with DaTSCAN™ SPECT in the clinical practice in our Parkinson-Center Csoti, I.
2009
15 S2 p. S51-
1 p.
artikel
342 P2.054 Exploring the effects of caffeine on men and women with movement disorders Seibert, P.
2009
15 S2 p. S103-
1 p.
artikel
343 P3.111 Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease Chan, P.
2009
15 S2 p. S176-
1 p.
artikel
344 P3.107 Expression of Integrins αv, β3, β1 and CD44 receptor may explain the neuroprotective effects of osteopontin Ailane, S.
2009
15 S2 p. S175-
1 p.
artikel
345 P2.071 Extrapontine myelinolysis after correction of hyponatremia presenting as acute parkinsonism Hanagasi, H.A.
2009
15 S2 p. S107-S108
2 p.
artikel
346 P1.222 Extrapontine myelinolysis and reversible parkinsonism Barinagarrementeria, F.
2009
15 S2 p. S86-
1 p.
artikel
347 P3.018 Factors affecting time to levodopa-induced dyskinesias Hassin-Baer, S.
2009
15 S2 p. S152-
1 p.
artikel
348 P1.142 Factors associated with functional performance of elderly people with Parkinson's disease – preliminary version Leandro, L.A.
2009
15 S2 p. S65-
1 p.
artikel
349 P1.041 Factor structure of the Geriatric Depression Scale in Turkish Parkinson's disease patients Ertan, T.
2009
15 S2 p. S39-
1 p.
artikel
350 P3.193 Familial aggregation of Parkinson's disease in the Greek island of Syros Bozi, M.
2009
15 S2 p. S197-
1 p.
artikel
351 P3.143 Ferroportin1 but not hephaestin was involved in the 6-hydroxydopamine induced iron accumulation in primary ventral mesencephalic neurons and MES23.5 cells Song, N.
2009
15 S2 p. S185-
1 p.
artikel
352 P2.077 First-in-class drugs with neuroprotective potential against Parkinson's disease identifled through biology-driven discovery approach Van Dooren, T.
2009
15 S2 p. S109-
1 p.
artikel
353 P3.188 Fluctuating symptoms, including sleep-disturbances, and metabolic/electrical rhythms that drive normal brain function may be forged by NAD+ bimodal circadian oscillations Williams, A.C.
2009
15 S2 p. S196-
1 p.
artikel
354 P2.126 Follow-up study of patients with varying stage Parkinson's disease in Hai, Tanzania, after 1 year of treatment with levodopa Dotchin, C.
2009
15 S2 p. S123-S124
2 p.
artikel
355 P3.043 FRDA mutation predates divergence of European and Indian populations of Indo-European origin? Srivastava, A.
2009
15 S2 p. S159-
1 p.
artikel
356 P1.154 Frequency of cognitive impairment and depression in Nigerians with Parkinson's disease Ojo, O.
2009
15 S2 p. S68-
1 p.
artikel
357 P1.020 Frontal assessment battery for evaluation of executive dysfunction in patients with Huntington's disease Tumas, V.
2009
15 S2 p. S34-
1 p.
artikel
358 P1.066 Frontal cortex disturbances in focal dystonia Ochudlo, S.
2009
15 S2 p. S45-S46
2 p.
artikel
359 P1.198 Frontal lobe lesions mimicking midbrain tremor Grimaldi, G.
2009
15 S2 p. S80-
1 p.
artikel
360 P1.206 Frontal systems behavioural syndromes in older Parkinson's disease patients Loftus, L.
2009
15 S2 p. S82-
1 p.
artikel
361 P1.074 Frontotemporal dementia and parkinsonism in a patient with a chronic mercury intoxication Ciordia, R.
2009
15 S2 p. S47-S48
2 p.
artikel
362 P3.139 Functional and design-based stereological assessment of the MPTP-induced heart atrophy in mice: a short communication Ladd, F.V.L.
2009
15 S2 p. S183-S184
2 p.
artikel
363 P3.187 GABAergic modulation in the protective effect of allopregnanolone in sleep deprivation-induced anxiety like behavior and oxidative damage in mice Kumar, A.
2009
15 S2 p. S196-
1 p.
artikel
364 P2.014 Gait analysis in a porcine model of progressive Parkinson disease established by chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication Mogensen, P.
2009
15 S2 p. S91-S92
2 p.
artikel
365 P2.015 Gait analysis in the Göttingen minipig model of Parkinson disease based on alpha synuclein overexpression in the substantia nigra Mogensen, P.
2009
15 S2 p. S92-
1 p.
artikel
366 P3.038 GBA mutations and clinical features of patients evaluated at a referral clinic for Parkinson disease Lopez, G.
2009
15 S2 p. S157-S158
2 p.
artikel
367 P3.030 GBA mutations and Parkinson disease in Italian population D'Angelo, R.
2009
15 S2 p. S155-S156
2 p.
artikel
368 P1.147 Gender differences in non-motor symptoms in Parkinson's disease Martinez-Martin, P.
2009
15 S2 p. S66-S67
2 p.
artikel
369 P1.063 Generalized dystonia treated with pallidal deep brain stimulation Brodacki, B.
2009
15 S2 p. S45-
1 p.
artikel
370 P1.062 Genetic contribution to young onset dystonia in a Taiwanese cohort Lu, C.-S.
2009
15 S2 p. S44-S45
2 p.
artikel
371 P1.080 Genetic mutations in ataxia–telangiectasia patients Karuta, S.
2009
15 S2 p. S49-
1 p.
artikel
372 P3.129 Genetic polymorphism of nicotinic acetylcholine receptor a4 subunit is associated with Parkinson's disease Lyros, E.
2009
15 S2 p. S181-
1 p.
artikel
373 P1.069 Genetic spectrum of dopa-responsive dystonia in the Polish families Rudzinska, M.
2009
15 S2 p. S46-
1 p.
artikel
374 P3.155 Genetic variability of histamine receptors in patients with Parkinson's disease Garcia-Gamito, F.J.
2009
15 S2 p. S188-
1 p.
artikel
375 P3.116 Genome-wide signiflcant conflrmation of SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease Edwards, T.
2009
15 S2 p. S178-
1 p.
artikel
376 P2.040 Gerotechnological aspects of DBS patient controllers: utility and futility Kaiser, I.
2009
15 S2 p. S99-
1 p.
artikel
377 P3.059 Glial activation in incidental Lewy body disease Ahn, T.-B.
2009
15 S2 p. S163-
1 p.
artikel
378 P1.049 Glial monoamine oxidase participates in deamination of dopamine formed from L-dopa in a rat model of Parkinsonian striatum Sader-Mazbar, O.
2009
15 S2 p. S41-
1 p.
artikel
379 P1.003 Glutamic acid to gamma-aminobutyric acid level proportion in Tourette syndrome patients is higher than in controls Janik, P.
2009
15 S2 p. S29-S30
2 p.
artikel
380 P3.152 Glutathione is reduced in neutrophils from patients with sporadic Parkinson's disease White, L.R.
2009
15 S2 p. S187-
1 p.
artikel
381 P1.034 Gray matter atrophy and glucose metabolism in dementia with Lewy bodies Kim, B.C.
2009
15 S2 p. S37-
1 p.
artikel
382 P2.072 Green tea exacerbates Haloperidol-induced Parkinsonism and changes Dopamine metabolism in nucleus accumbens Malik, T.
2009
15 S2 p. S108-
1 p.
artikel
383 P2.190 Growth factors secreted by retinal pigment epithelial cells provide survival advantage to dopaminergic neurons Subramanian, T.
2009
15 S2 p. S141-
1 p.
artikel
384 P3.090 Heterozygous mutations in PINK1 kinase domain exert a gene dosage effect Angeles, D.
2009
15 S2 p. S171-
1 p.
artikel
385 P2.039 High frequency of genetically-determined Parkinson's disease in patients referred to deep brain stimulation Johansen, K.
2009
15 S2 p. S98-S99
2 p.
artikel
386 P3.128 1H-MRS after bilateral DBS of the STN in Parkinson's disease Llumiguano, C.
2009
15 S2 p. S180-S181
2 p.
artikel
387 P3.127 1H-MRS and cognitive function changes after bilateral DBS of the STN in Parkinson's disease Llumiguano, C.
2009
15 S2 p. S180-
1 p.
artikel
388 P1.083 Homocysteinemia, postural instability and risk of falls in non-demented patients with Parkinson's disease Munhoz, R.
2009
15 S2 p. S50-
1 p.
artikel
389 P1.011 How do initial symptoms of Parkinson's disease and the patients' awareness of the disease affect the process of diagnosis? Chiba, H.
2009
15 S2 p. S31-
1 p.
artikel
390 P3.170 How effective is the WII program as physical therapy intervention of patient with Parkinson's disease? Alvarez, M.
2009
15 S2 p. S192-
1 p.
artikel
391 P1.143 How important is unrelated co-morbidity in Parkinson's disease? Leckie, K.
2009
15 S2 p. S65-
1 p.
artikel
392 P1.209 How to treat dementia in Parkinsonian patients? Werner, F.-M.
2009
15 S2 p. S82-S83
2 p.
artikel
393 P1.027 How was cognition affected in cases of pellagra? Williams, A.C.
2009
15 S2 p. S35-S36
2 p.
artikel
394 P3.198 Hyperacetylation and nuclear shuttling of Ku70 during neurotoxic insults in Parkinson's disease models: a novel oxidative signaling in dopaminergic neurodegeneration Kanthasamy, A.
2009
15 S2 p. S198-S199
2 p.
artikel
395 P2.068 Hypodipsia discriminates progressive supranuclear palsy from Parkinson's disease and multiple system atrophy Stamelou, M.
2009
15 S2 p. S107-
1 p.
artikel
396 P3.176 Idiopathic restless legs syndrome in Parkinson's disease – a risk factor or a chance association? Boczarska-Jedynak, M.
2009
15 S2 p. S193-
1 p.
artikel
397 P1.043 Illness perceptions and depression in Parkinson's disease Hurt, C.
2009
15 S2 p. S40-
1 p.
artikel
398 P1.203 Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study Schapira, A.
2009
15 S2 p. S81-
1 p.
artikel
399 P3.064 Immunohistochemical study of the progression of neurodegenerative process within the striatum of rats transgenic for Huntington's disease Guncova, I.
2009
15 S2 p. S164-S165
2 p.
artikel
400 P2.127 Impact of a French consensus conference on the initial therapy of Parkinson's disease: a population-based study Fayard, C.
2009
15 S2 p. S124-
1 p.
artikel
401 P1.045 Impact of L-Carnitine and desferrioxamine on antioxidants and neurochemical hormones in 6-hydroxydopamine-induced neurotoxicity in the dopaminergic neurones of aged rats Kumar, P.
2009
15 S2 p. S40-
1 p.
artikel
402 P2.036 Impact of post-DBS pneumocephalus to coordinates deviation of the electrodes Huang, H.M.
2009
15 S2 p. S98-
1 p.
artikel
403 P3.122 Impaired cerebral glucose metabolism and atrophy, but not amyloid accumulation is related to cognitive impairment in Parkinson's disease Jokinen, P.A.
2009
15 S2 p. S179-
1 p.
artikel
404 P3.145 Impaired cortical connectivity modulation in Parkinson's disease patients performing a visually-guided joystick task Tropini, G.
2009
15 S2 p. S185-
1 p.
artikel
405 P3.105 Impaired visuomotor adaptation in Parkinson disease during a computer-mediated aiming task Lhuisset, L.
2009
15 S2 p. S175-
1 p.
artikel
406 P3.163 Impairment of the dynamic visual acuity in patients with Parkinson's disease Taweekarn, P.
2009
15 S2 p. S190-
1 p.
artikel
407 P3.183 Implications of deep brain stimulation on sleep disturbances for individuals with movement disorders Seibert, P.
2009
15 S2 p. S195-
1 p.
artikel
408 P1.229 Improvement of motor and non-motor symptoms after switching from oral therapy to continuous duodenal levodopa infusion in advanced Parkinson's disease Antonini, A.
2009
15 S2 p. S88-
1 p.
artikel
409 P2.108 Improvements in symptom severity and daily living with saflnamide in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study Szasz, J.
2009
15 S2 p. S118-
1 p.
artikel
410 P1.158 Incidence and predictors of dementia in the PD MED trial Patel, S.
2009
15 S2 p. S69-
1 p.
artikel
411 P2.139 Incidence and predictors of motor complications in the PD MED trial Ives, N.
2009
15 S2 p. S127-
1 p.
artikel
412 P1.176 Incidence of hip fracture in Parkinson disease: a population-based study in British Columbia, Canada Wieler, M.
2009
15 S2 p. S74-
1 p.
artikel
413 P1.013 Independence of striatal dopaminergic and cardiac noradrenergic denervation in synucleinopathies Goldstein, D.
2009
15 S2 p. S32-
1 p.
artikel
414 P1.215 Indian variant PSP-P: clinical and quantitative MRI proflle Nehru, R.
2009
15 S2 p. S84-
1 p.
artikel
415 P3.162 Individuals with Parkinson's disease and dysarthria deflne communicative effectiveness Donovan, N.
2009
15 S2 p. S189-S190
2 p.
artikel
416 P3.134 Infectious causes of parkinsonism Munhoz, R.
2009
15 S2 p. S182-
1 p.
artikel
417 P3.086 Influence of oxidative stress and apoptosis on the onset and progression of Parkinson's disease in rotenone induced experimental model Nehru, B.
2009
15 S2 p. S170-
1 p.
artikel
418 P1.226 Influence of visual and auditory cues in patients with Parkinson's disease Maki, T.
2009
15 S2 p. S87-
1 p.
artikel
419 P3.123 Inhibitory plasticity is impaired in early untreated Parkinson's disease Joseph, T.
2009
15 S2 p. S179-S180
2 p.
artikel
420 P2.120 iNOS-but not nNOS-inhibition protects against 6-OHDA-induced nigral cell loss in an animal model of PD Brzozowski, M.J.
2009
15 S2 p. S122-
1 p.
artikel
421 P3.101 Interactive effects of LRRK2 and a-synuclein Sen, S.
2009
15 S2 p. S174-
1 p.
artikel
422 P1.061 Interoceptive mirroring to guide assessment of writer's cramp Lim, E.
2009
15 S2 p. S44-
1 p.
artikel
423 P2.133 Intracerebral application of botulinum toxin into Wistar rats – neuroanatomic aspects Hawlitschka, A.
2009
15 S2 p. S125-
1 p.
artikel
424 P1.058 Intracranial granulomas presenting as extrapyramidal disorder: a report of three cases Jha, S.
2009
15 S2 p. S43-S44
2 p.
artikel
425 P2.002 Intranigral injection of CDNF promotes functional recovery of nigrostriatal dopaminergic circuit in a lesion model of Parkinson's disease Bäck, S.
2009
15 S2 p. S88-S89
2 p.
artikel
426 P2.034 Intraoperative stereotactic accuracy of the FHC microTargeting and Axon Instruments microdrives compared Ahmed, S.
2009
15 S2 p. S97-
1 p.
artikel
427 P3.110 Is the basal ganglia involved in subconscious processing? A direct comparison of conscious & subconscious processing in individuals with Parkinson's disease Brown, M.
2009
15 S2 p. S176-
1 p.
artikel
428 P1.110 123I-/V-cu-fluoro-propyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ([123I] FP-CIT) SPECT in cases of multiple system atrophy Gontu, V.
2009
15 S2 p. S57-
1 p.
artikel
429 P3.151 Latencies of vagus sensory evoked potentials are prolonged in Parkinson's disease Weise, D.
2009
15 S2 p. S187-
1 p.
artikel
430 P3.174 Laughing during sleep as a manifestation of rapid eye movement sleep behaviour disorder Siclari, F.
2009
15 S2 p. S193-
1 p.
artikel
431 P1.002 Lesch-Nyhan syndrome, a metabolic and behavioral correlation Jimenez Botello, L.C.
2009
15 S2 p. S29-
1 p.
artikel
432 P2.083 Level of oxidative DNA damage and expression of apoptotic proteins in patients with Parkinson's disease treatment with L-dopa Dorszewska, J.
2009
15 S2 p. S111-
1 p.
artikel
433 P2.202 Levodopa pharmacokinetics following administration of novel gastric retentive extended-release formulations compared to a reference extended-release tablet in Parkinson's disease patients Stolyarov, I.D.
2009
15 S2 p. S144-
1 p.
artikel
434 P3.041 LINGO1 variant increases risk of familial essential tremor Prakash, K.M.
2009
15 S2 p. S158-
1 p.
artikel
435 P2.020 Lipopolysaccharide rat model for Parkinson's disease neurodegeneration: disease-associated proteins, cytokines and inflammatory cells in brain tissue Schiess, M.
2009
15 S2 p. S93-
1 p.
artikel
436 P1.163 Longitudinal assessment of flne motor control: transition from normal control to onset of Parkinson's disease Shrairman, R.
2009
15 S2 p. S70-S71
2 p.
artikel
437 P1.086 Long-term effect of varenicline (Chantix®) in four ataxic patients: prolonged symptomatic beneflt following drug discontinuation Zesiewicz, T.
2009
15 S2 p. S50-S51
2 p.
artikel
438 P2.145 Long-term effects of amantadine for levodopa-induced dyskinesias and motor impairment in Parkinson's disease: retrospective report Kuno, S.
2009
15 S2 p. S128-S129
2 p.
artikel
439 P2.132 Long-term safety and patient preference for dose frequency in patients receiving ropinirole prolonged release in early or advanced Parkinson's disease Hauser, R.A.
2009
15 S2 p. S125-
1 p.
artikel
440 P2.174 Long-term safety of rotigotine transdermal patch in early-stage Parkinson's disease: four year results Watts, R.
2009
15 S2 p. S137-
1 p.
artikel
441 P3.035 Loss of CAA interruption in large SCA2 alleles is a risk factor to ATX2 gene instability Lafflta-Mesa, J.
2009
15 S2 p. S157-
1 p.
artikel
442 P3.070 Loss of noradrenergic neurons in the locus coeruleus of Parkinson's disease subjects does not result in compensation Szot, P.
2009
15 S2 p. S166-
1 p.
artikel
443 P3.097 LRRK2 diagnostic types and neuropathological forms: surgical spectrum – results comprehensive methods Echebarria Mendieta, S.G.
2009
15 S2 p. S173-
1 p.
artikel
444 P3.191 LRRK2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications Qing, H.
2009
15 S2 p. S197-
1 p.
artikel
445 P2.076 MANF: a new potential disease-modifying drug candidate for Parkinson's disease Commissiong, J.
2009
15 S2 p. S109-
1 p.
artikel
446 P1.072 Mapping motor and somatosensory cortical flnger representation in focal hand dystonia Weise, D.
2009
15 S2 p. S47-
1 p.
artikel
447 P2.057 Medicinal therapy as an alternative of deep brain stimulation in the management of Levo-Dopa induced dyskinesia in Parkinson's disease Subhani, F.U.H.
2009
15 S2 p. S104-
1 p.
artikel
448 P2.140 Meta-analysis of DBS surgery in patients with advanced Parkinson's disease Ives, N.
2009
15 S2 p. S127-
1 p.
artikel
449 P2.157 Metabotropic glutamate receptor type 5 (mGluR5) antagonists improve L-DOPA-induced-dyskinesia in both rat and macaque models of Parkinson's disease Rylander, D.
2009
15 S2 p. S132-
1 p.
artikel
450 P3.052 Metallomics of neuromelanin in Parkinsonian syndromes Bohic, S.
2009
15 S2 p. S161-S162
2 p.
artikel
451 P2.006 Mice differ from rats: detection of tyrosine hydroxylase expressing striatal neurons after 6-OHDA-injection in the mouse brain Haas, S.J.P.
2009
15 S2 p. S89-S90
2 p.
artikel
452 P3.067 Mice infected with highly pathogenic H5N1 influenza virus develop Parkinsonian pathology Jang, H.
2009
15 S2 p. S165-
1 p.
artikel
453 P3.150 Microglial activation and age-related damage of dopaminergic neurodegeneration in MPTP-treated SAMP8 mice Liu, J.
2009
15 S2 p. S186-S187
2 p.
artikel
454 P3.089 Microglial MAC1 and PI3K are essential in mediating beta-amyloid peptide-induced neurotoxicity in neuron/glia cultures Zhang, D.
2009
15 S2 p. S171-
1 p.
artikel
455 P1.098 Microstructural integrity of white matter in patients with Parkinson's disease (PD): diffusion tensor imaging and MR-tractography study Rozhkova, Z.
2009
15 S2 p. S54-
1 p.
artikel
456 P3.102 Mitochondrial defects induced by a loss of fusion effect in mutant PINK1 can be rescued through the flssion/fusion pathway Cui, M.
2009
15 S2 p. S174-
1 p.
artikel
457 P3.091 Mitochondrial morphology and function in PINK1-deflcient cells and mice Huang, Z.
2009
15 S2 p. S171-S172
2 p.
artikel
458 P3.072 Mitochondrial NAD(H) suppliers rate-limit energy, signal transduction and redox-gradient spatio-temporal variables important for development and degeneration: lessons from Pellagra Williams, A.C.
2009
15 S2 p. S167-
1 p.
artikel
459 P2.062 MLPA analysis in EOP patients Barzaghi, C.
2009
15 S2 p. S105-
1 p.
artikel
460 P3.007 Modeling synucleinopathies: intracellular delivery of alpha-synuclein oligomers via protein transfection results in intracellular alpha-synuclein inclusions Martone, R.
2009
15 S2 p. S149-
1 p.
artikel
461 P3.002 Modiflcation by dopamine adducts links a-synuclein to oxidative stress in Parkinson's disease Bisaglia, M.
2009
15 S2 p. S148-
1 p.
artikel
462 P3.004 Modulation of alpha synuclein aggregation by fllamentous phages Dimant, H.
2009
15 S2 p. S148-
1 p.
artikel
463 P2.119 Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 in a parkinsonian animal model Bousquet, M.
2009
15 S2 p. S121-S122
2 p.
artikel
464 P3.098 Molecular analysis PARK2 and DJ-1 mutations in Polish early onset Parkinson's disease patients Koziorowski, D.
2009
15 S2 p. S173-
1 p.
artikel
465 P2.192 Molecular diagnostics of parkinsonism in asymptomatic subjects at high risk for disease onset and progression Pasinetti, G.
2009
15 S2 p. S142-
1 p.
artikel
466 P1.180 More addict because Parkinsonian? de Chazeron, I.
2009
15 S2 p. S75-
1 p.
artikel
467 P3.062 Most cases with Lewy pathology in a population-based cohort adhere to the pattern of progression suggested by Braak LB staging Duda, J.E.
2009
15 S2 p. S164-
1 p.
artikel
468 P1.193 Motor cortical excitatory plasticity is severely impaired in de novo Parkinson's disease and is improved by chronic pramipexole treatment Kishore, A.
2009
15 S2 p. S78-S79
2 p.
artikel
469 P1.195 Motor symptom relief by repetitive transcranial magnetic stimulation in patients with multiple system atrophy Wang, H.
2009
15 S2 p. S79-
1 p.
artikel
470 P3.077 Movement disorder among new Parkinson's disease patients in China Luo, Y.
2009
15 S2 p. S168-
1 p.
artikel
471 P3.021 Movement disorders after stroke Motuzova, Y.
2009
15 S2 p. S153-
1 p.
artikel
472 P3.081 Movement related frequency modulation of alpha oscillatory activity in human basal ganglia Singh, A.
2009
15 S2 p. S169-
1 p.
artikel
473 P3.076 Movement related potentials in Parkinson's disease patients Klepac, N.
2009
15 S2 p. S168-
1 p.
artikel
474 P3.048 MPTP-reactive “in situ” inflammation as a key event in the molecular cascade linking nigrostriatal injury to repair L'Episcopo, F.
2009
15 S2 p. S160-
1 p.
artikel
475 P2.113 Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD) Marks Jr, W.
2009
15 S2 p. S120-
1 p.
artikel
476 P3.100 Mutant (I2020T) LRRK2 has higher susceptibility to proteolysis and impaired protectivity against apoptosis Ohta, E.
2009
15 S2 p. S174-
1 p.
artikel
477 P3.025 Mutation analysis of the glucocerebrosidase gene in Russian patients with Parkinson's disease Abramycheva, N.Y.
2009
15 S2 p. S154-
1 p.
artikel
478 P1.070 Mutations in the THAP1 (DYT6) gene - a cause of generalized dystonia with prominent spasmodic dysphonia Schneider, S.A.
2009
15 S2 p. S46-S47
2 p.
artikel
479 P1.210 Negative reactions to receiving spousal care in older Parkinson's disease patients: the role of depression Loftus, L.
2009
15 S2 p. S83-
1 p.
artikel
480 P2.189 Neural stem cell mediated neuroprotection in a rat model of Parkinson's disease: role of endogenous precursors and graft-expressed molecules Madhavan, L.
2009
15 S2 p. S141-
1 p.
artikel
481 P1.016 Neural transplants in patients with Huntington's disease undergo disease-speciflc neuronal degeneration Cicchetti, F.
2009
15 S2 p. S33-
1 p.
artikel
482 P3.173 Neuroanatomical aspect of the diencephalospinal dopaminergic pathway in the non human primate Barraud, Q.
2009
15 S2 p. S192-S193
2 p.
artikel
483 P1.006 Neurochemical and neuroplastic changes in chronic methyphenidate administered brains Sadasivan, S.
2009
15 S2 p. S30-
1 p.
artikel
484 P3.147 Neurodegenerative markers in CSF in patients suffering from Parkinson's disease Vranová, H.
2009
15 S2 p. S186-
1 p.
artikel
485 P1.056 Neuroleptic-induced tardive cervical dystonia: clinical series of 20 patients Godeiro-Junior, C.
2009
15 S2 p. S43-
1 p.
artikel
486 P3.168 Neurologic rehabilitation in cervical dystonia: study of 20 cases Ribeiro, M.
2009
15 S2 p. S191-
1 p.
artikel
487 P1.005 Neurologic soft signs in obsessive compulsive Egyptian patients and its correlation with the severity of obsessive compulsive symptoms Moustafa, H.
2009
15 S2 p. S30-
1 p.
artikel
488 P3.066 Neuropathological characterization of posttranslationally modifled a-synuclein in PD and DLB Hilton, K.
2009
15 S2 p. S165-
1 p.
artikel
489 P2.102 Neuroprotective and anti-inflammatory properties of novel pyrazolyl-2,4-thiazolidinediones Youssef, A.M.
2009
15 S2 p. S116-
1 p.
artikel
490 P2.008 Neuroprotective effect of GLP-1R agonist exendin-4 in rat model of Parkinson's disease involves D3-receptor mediated changes in neural precursor cells Harkavyi, A.
2009
15 S2 p. S90-
1 p.
artikel
491 P1.018 Neuroprotective effect of neuroimmunophilins against 3-nitropropionic acid induced Huntington's chorea like symptoms: possible cognitive dysfunction and biochemical and cellular alterations Kumar, P.
2009
15 S2 p. S33-
1 p.
artikel
492 P2.016 Neuroprotective effects of VEGF-C in the 6-OHDA rat model of Parkinson's disease Piltonen, M.
2009
15 S2 p. S92-
1 p.
artikel
493 P2.130 Neuroprotective mechanisms of cystamine in a murine model of Parkinson's disease Gibrat, C.
2009
15 S2 p. S124-S125
2 p.
artikel
494 P2.079 Neuroprotective properties of Poacynum against MPP+-toxicity to dopaminergic cells Rausch, W.D.
2009
15 S2 p. S110-
1 p.
artikel
495 P2.046 Neuropsychological outcome after unilateral STN DBS: a comparison of English-speakers and Spanish-speakers Marion, I.B.
2009
15 S2 p. S100-
1 p.
artikel
496 P3.088 Nicotinamide dosage regulates redox [NAD(H)] and is relevant to pellagra, brain development and diseases of ageing including dementia and parkinsonism Williams, A.C.
2009
15 S2 p. S171-
1 p.
artikel
497 P3.189 Nicotinamide phosphoribosyltransferase (Nampt) generates NAD+, regulates SIRTs, and differentiates & maintains haematopoietic and neural stem/progenitor cells: conflrmation from Pellagra Williams, A.C.
2009
15 S2 p. S196-S197
2 p.
artikel
498 P1.104 Night time eating in Parkinson's disease, a new aspect of punding? Reddy, P.
2009
15 S2 p. S55-S56
2 p.
artikel
499 P3.065 Nimesulide, a preferential cyclooxygenase-2 inhibitor exhibits neuroprotection against MPTP-induced striatal lesions in rats: behavioral, biochemical, cellular and histological evidences Gupta, A.
2009
15 S2 p. S165-
1 p.
artikel
500 P1.156 Non-motor comorbidities in patients with Parkinson's disease: a US claims database analysis Papapetropoulos, S.
2009
15 S2 p. S69-
1 p.
artikel
501 P1.121 Non-motor symptoms in different Parkinson disease stages Bosca-Blasco, M.E.
2009
15 S2 p. S60-
1 p.
artikel
502 P3.040 Non synonymous GIGYF2 variants in Parkinson's disease Prakash, K.M.
2009
15 S2 p. S158-
1 p.
artikel
503 P2.172 Nordic Walking in Parkinson's disease: improves walking condition but leaves stride length unchanged van Eijkeren, F.J.M.
2009
15 S2 p. S136-
1 p.
artikel
504 P3.085 Novel bio-panning technique to isolate scFv against low concentrations of toxic natural brain derived Abeta oligomers Kasturirangan, S.
2009
15 S2 p. S170-
1 p.
artikel
505 P1.057 Novel compound heterozygous tyrosine hydroxylase mutations in two DOPA-responsive dystonia patients Haugarvoll, K.
2009
15 S2 p. S43-
1 p.
artikel
506 P1.050 Novel neuroprotective agents for the treatment of Parkinson's disease George, J.
2009
15 S2 p. S41-S42
2 p.
artikel
507 P2.028 8-OHdG in cerebrospinal fluid as a marker of oxidative stress in various neurodegenerative diseases Zerr, I.
2009
15 S2 p. S96-
1 p.
artikel
508 P2.153 Once-daily pramipexole extended-release (ER) demonstrated non-inferiority compared to immediate release (IR) tid dosing in early Parkinson's disease Poewe, W.
2009
15 S2 p. S131-
1 p.
artikel
509 P2.166 Once-daily ropinirole prolonged release improves activities of daily living and motor symptoms in patients with advanced Parkinson's disease Stocchi, F.
2009
15 S2 p. S135-
1 p.
artikel
510 P1.055 Open-label naturalistic study of pregabalin for cervical dystonia and other hyperkinetic movement disorders (HMDs): effectiveness and tolerability Chen, J.
2009
15 S2 p. S43-
1 p.
artikel
511 P3.047 Opsoclonus–myoclonus syndrome in anti-NMDA-receptor encephalitis Horvath, J.
2009
15 S2 p. S160-
1 p.
artikel
512 P2.026 Optimizing olfactory testing for the diagnosis of Parkinson's disease Morley, J.
2009
15 S2 p. S95-
1 p.
artikel
513 P3.023 Parakinesia Brachialis Oscitans due to brainstem stroke. Report of two cases Munhoz, R.P.
2009
15 S2 p. S154-
1 p.
artikel
514 P1.179 Parkinsonian diseases neurological diseases associated with longest neuropsychiatric inpatient admissions Appel-Cresswell, S.
2009
15 S2 p. S75-
1 p.
artikel
515 P3.108 Parkinsonism in Jamaica: a 3-year prospective study Ali, A.
2009
15 S2 p. S175-S176
2 p.
artikel
516 P3.125 Parkinsons disease among Inuit in Greenland: persistent organic pollutions as risk factors Koldkjær, O.
2009
15 S2 p. S180-
1 p.
artikel
517 P1.091 Parkinson's disease and pathological gambling: results from a fMRI study investigating cue induced brain activity Frosini, D.
2009
15 S2 p. S52-
1 p.
artikel
518 P1.134 Parkinson's disease and politeness Holtgraves, T.
2009
15 S2 p. S63-
1 p.
artikel
519 P1.141 Parkinson's disease distribution within the VA health care system in flscal years 2003–2008 Lai, E.C.
2009
15 S2 p. S65-
1 p.
artikel
520 P2.167 Parkinson's disease drug therapies: medication compliance and persistence Tarrants, M.
2009
15 S2 p. S135-
1 p.
artikel
521 P1.183 Parkinson's Disease Psychosis (PDP): A condition which is undertreated Lio, F.M.
2009
15 S2 p. S76-
1 p.
artikel
522 P1.181 Parkinson's Disease Psychosis (PDP): An under-diagnosed condition in spite of its prevalence and impact Fernandez, H.
2009
15 S2 p. S75-
1 p.
artikel
523 P2.210 Parkinson's disease registry Krivonos, O.
2009
15 S2 p. S147-
1 p.
artikel
524 P3.199 Parkinson's disease–smoking: still a dilemma? Mititelu, A.
2009
15 S2 p. S199-
1 p.
artikel
525 P1.146 Parkinson's disease staging based of the non-motor symptoms scale Martinez-Martin, P.
2009
15 S2 p. S66-
1 p.
artikel
526 P1.127 Parkinson's disease subtypes and their relevance to studies of disease-modifying agents Elm, J.
2009
15 S2 p. S61-
1 p.
artikel
527 P2.125 Parkinson's disease treatments in practice: evidence from the PD MED trial Clarke, C.
2009
15 S2 p. S123-
1 p.
artikel
528 P2.047 ParkinTune: automated Parkinson's disease motor symptom assessment for deep brain stimulation programming Mera, T.
2009
15 S2 p. S101-
1 p.
artikel
529 P3.094 Pathological and clinical series in LRRK2 Parkinson's disease and ATG16L1 Crohn's disease: autophagy models comparative Echebarria Mendieta, S.G.
2009
15 S2 p. S172-
1 p.
artikel
530 P1.060 Pathological observations in seven cases with neurodegeneration with brain iron accumulation (NBIA) with mutations in PANK2 and PLA2G6 Li, A.
2009
15 S2 p. S44-
1 p.
artikel
531 P2.088 Patient and carer opinions of apomorphine use in Parkinson's disease O'Sullivan, S.
2009
15 S2 p. S112-
1 p.
artikel
532 P3.005 PD patients with the E46K mutation in the alpha-synuclein gene, flve years later Gomez Esteban, J.C.
2009
15 S2 p. S149-
1 p.
artikel
533 P3.165 Peculiarities of parameter's changes of vertical posture in Parkinson's disease Ivashynka, A.
2009
15 S2 p. S190-
1 p.
artikel
534 P3.014 Pellagra: American epidemic of a curable, familial, neurodegenerative, immune-deflcient, metabolic and bioenergetic “redox” disorder. Tip of NAD(H) iceberg? Williams, A.C.
2009
15 S2 p. S151-
1 p.
artikel
535 P1.108 Periaqueductal T2-weighted MRI hyperintensity in early stage progressive supranuclear palsy de Verdal, M.
2009
15 S2 p. S56-
1 p.
artikel
536 P1.125 Peripheral nerves injury in the central nervous system degeneration (Parkinson's disease): pilot study Chovancova, Z.
2009
15 S2 p. S61-
1 p.
artikel
537 P3.138 Perturbation of protein thiol homeostasis through downregulation of glutaredoxin, a protein disulflde oxidoreductase, results in loss of DJ-1 through proteolysis Ray, A.
2009
15 S2 p. S183-
1 p.
artikel
538 P3.194 Perturbation of tyrosine by cationic charge Vezzoli, G.
2009
15 S2 p. S197-S198
2 p.
artikel
539 P1.102 Pharmacological MRI detecting dysfunctions of the nigrostriatal system and monitoring therapeutic effects in PD Zhang, Z.
2009
15 S2 p. S55-
1 p.
artikel
540 P1.015 Physical therapy intervention for people with Huntington disease Adwan, Z.
2009
15 S2 p. S32-
1 p.
artikel
541 P2.109 Piclozotan reduces dyskinesia and OFF time in Parkinson's disease (PD) patients with L-dopa induced motor complications Hauser, R.A.
2009
15 S2 p. S118-
1 p.
artikel
542 P2.085 Piribedil stimulates dopaminergic neurons via dopamine receptor activation and PI3-kinase signalling and protects against MPP+ toxicity Leideck, C.
2009
15 S2 p. S111-
1 p.
artikel
543 P3.153 PLA2G6 mutations in a Taiwanese cohort of early onset parkinsonism Wu-Chou, Y.-H.
2009
15 S2 p. S187-
1 p.
artikel
544 P3.029 Polymorphisms in aldehyde dehydrogenase and the risk of sporadic Parkinson disease Galvin, J.
2009
15 S2 p. S155-
1 p.
artikel
545 P3.039 Polymorphisms in the transcription factor gene GATA2 and GATA-2 target region in a-synuclein (SNCA) are associated with Parkinson's disease (PD) Kay, D.
2009
15 S2 p. S158-
1 p.
artikel
546 P3.017 Posterior alien hand phenomena as the flrst manifestation of HIV encephalopathy Munhoz, R.
2009
15 S2 p. S152-
1 p.
artikel
547 P1.076 Postural control differs between Parkinson disease sub-types Dibble, L.
2009
15 S2 p. S48-
1 p.
artikel
548 P2.122 PPAR-gamma agonist rosiglitazone stops the progressive dopaminergic degeneration induced by chronic MPTP in mice Carta, A.
2009
15 S2 p. S122-
1 p.
artikel
549 P1.133 Pragmatic comprehension deflcit in Parkinson's disease Holtgraves, T.
2009
15 S2 p. S63-
1 p.
artikel
550 P2.211 Predicting response to doxazosin in patients with voiding dysfunction and Parkinson disease: impact of the neurological impairment Gomes, C.
2009
15 S2 p. S147-
1 p.
artikel
551 P3.135 Predictive factors for PD progression – preliminary results of PARKMIP/COPARK cohort after 24-months follow up Negre-Pages, L.
2009
15 S2 p. S182-S183
2 p.
artikel
552 P1.103 Predictors of impulse control disorders in MMPI-2 in patients suffering from Parkinson's disease: a pilot study Farnikova, K.
2009
15 S2 p. S55-
1 p.
artikel
553 P1.197 Presynaptic dopaminergic dysfunction on [123I]-FP-CIT SPECT in patients with long standing essential tremor with associated rest tremor Castelnovo, G.
2009
15 S2 p. S79-S80
2 p.
artikel
554 P3.158 Prevalence and associated factors of falls among people with Parkinson's disease Adwan, Z.
2009
15 S2 p. S188-S189
2 p.
artikel
555 P2.138 Prevalence and improvement of comprehensive (non-motor) symptom assessment after prolonged-release ropinirole (Requip XL) Isaacson, J.
2009
15 S2 p. S127-
1 p.
artikel
556 P1.137 Prevalence of constipation in Chinese Parkinson's disease patients in a regional hospital in Hong Kong Hui, K.F.
2009
15 S2 p. S64-
1 p.
artikel
557 P1.199 Prevalence of essential tremor in Nigeria: a community based multi-stage study Okubadejo, N.
2009
15 S2 p. S80-
1 p.
artikel
558 P1.172 Prevalence of non-motor symptoms in Thai Parkinson's disease patients Vongvaivanich, K.
2009
15 S2 p. S73-
1 p.
artikel
559 P2.073 Prevalence of parkinsonism and other movement disorders in outpatients with Alzheimer's disease using cholinesterase inhibitors and/or memantine Munhoz, R.P.
2009
15 S2 p. S108-
1 p.
artikel
560 P1.078 Preventing falls in Parkinson's disease: the GETuP trial Goodwin, V.
2009
15 S2 p. S49-
1 p.
artikel
561 P1.211 Preventing falls in Parkinson's disease: the GETuP trial Goodwin, V.
2009
15 S2 p. S83-
1 p.
artikel
562 P1.212 Primary progressive freezing gait – A clinical study from South India Mathew, R.
2009
15 S2 p. S83-
1 p.
artikel
563 P2.053 Primary Segmental Dystonia: 4 year follow-up of 11 patients treated with GPi deep brain stimulation Sarubbo, S.
2009
15 S2 p. S102-S103
2 p.
artikel
564 P3.095 Prodromical essential tremor and tremor-predominant LRRK2 mutation Parkinson's disease. Possible optimal VIM DBS results respect to pallidotomy-STN DBS? Echebarria Mendieta, S.G.
2009
15 S2 p. S172-S173
2 p.
artikel
565 P1.152 Proflles of apathy and depression in Parkinson's disease Myerson, C.
2009
15 S2 p. S68-
1 p.
artikel
566 P3.019 Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid Kulkarni, S.
2009
15 S2 p. S152-S153
2 p.
artikel
567 P3.024 Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-Dopa PET study Pavese, N.
2009
15 S2 p. S154-
1 p.
artikel
568 P2.010 Progressive MPTP non-human primate models that recapitulate non-motor symptoms of Parkinson's disease Hill, M.
2009
15 S2 p. S90-S91
2 p.
artikel
569 P3.020 Protective effects of Nigella sativa on the neuronal alterations of the striatum induced by haloperidol Malik, T.
2009
15 S2 p. S153-
1 p.
artikel
570 P3.044 Protein homeostasis involves chaperone functions of NMNAT alongside NAD production from nicotinamide, an essential dietary constituent: nicotinamide homeostasis is important Williams, A.C.
2009
15 S2 p. S159-
1 p.
artikel
571 P3.071 Protonopathies: deflciency or excess of proton providers and carriers (glucose and nicotinamide) may overwhelm NAD recycling and “short circuit” defenses Williams, A.C.
2009
15 S2 p. S166-S167
2 p.
artikel
572 P1.059 Psychiatric manifestations in dystonia Khan, S.
2009
15 S2 p. S44-
1 p.
artikel
573 P1.188 Psychogenic movement disorders – a Brazilian series of 72 cases Helio, T.
2009
15 S2 p. S77-
1 p.
artikel
574 P1.189 Psychogenic parkinsonism: case report Sichinava, D.
2009
15 S2 p. S77-S78
2 p.
artikel
575 P2.100 Pulsed electromagnetic flelds modulate nitric oxide pathways in dopaminergic neurons Casper, D.
2009
15 S2 p. S115-S116
2 p.
artikel
576 P2.201 PYM50028 (Cogane™) is a small molecule inducer of GDNF and BDNF that reverses behavioural impairment in MPTP-lesioned macaques Johnston, T.H.
2009
15 S2 p. S144-
1 p.
artikel
577 P1.119 Quality of life in Chilean Parkinson's disease patients: assessment using the World Health Organization Quality of Life Instrument Short Form Aránguiz, R.
2009
15 S2 p. S59-
1 p.
artikel
578 P2.178 Quality of life in patient with Parkinson's disease in Russia Guekht, A.
2009
15 S2 p. S138-
1 p.
artikel
579 P2.194 Quantitative assessment of medication on flnger tapping in Parkinson's disease Yokoe, M.
2009
15 S2 p. S142-
1 p.
artikel
580 P3.037 Quantitative proteomic analysis of substantia nigra in patients with Parkinson's disease Licker, V.
2009
15 S2 p. S157-
1 p.
artikel
581 P1.094 Radiation risks: a test of perception McKenzie, J.
2009
15 S2 p. S53-
1 p.
artikel
582 P2.082 Randomized crossover study to compare levodopa pharmacokinetics of three gastric retentive extended-release tablets versus a reference extended-release tablet in dog Cowles, V.
2009
15 S2 p. S110-S111
2 p.
artikel
583 P1.208 Randomized placebo-controlled trial of memantine for dementia in Parkinson's disease Marsh, L.
2009
15 S2 p. S82-
1 p.
artikel
584 P3.149 Rare deletion in the tyrosine hydroxylase gene contributes to Parkinson disease risk Wang, L.
2009
15 S2 p. S186-
1 p.
artikel
585 P2.141 Rasagiline provides symptomatic beneflt in early Parkinson's disease (PD) Jankovic, J.
2009
15 S2 p. S127-S128
2 p.
artikel
586 P2.131 Rate of antiparkinsonian medication increase after bilateral deep brain stimulation of the subthalamic nucleus Gill, C.
2009
15 S2 p. S125-
1 p.
artikel
587 P1.130 Rater training on UPDRS: assessing raters' ratings Gaur, R.
2009
15 S2 p. S62-
1 p.
artikel
588 P1.105 rCBF changes associated with pathological gambling in Parkinson's disease: a H2 15O PET study Van Eimeren, T.
2009
15 S2 p. S56-
1 p.
artikel
589 P2.018 Recapitulation of neurodegenerative disease and apoptotic neuronal cell death caused by 26S proteasome dysfunction Rezvani, Z.N.
2009
15 S2 p. S92-S93
2 p.
artikel
590 P2.146 Receptor proflle of lisuride at monoaminergic receptors contributes to its high efflcacy in Parkinson's disease and Restless Legs Syndrome Latté, K.P.
2009
15 S2 p. S129-
1 p.
artikel
591 P3.092 Recessive parkinsonism genes influence mitochondrial function under conditions of oxidative stress McCoy, M.
2009
15 S2 p. S172-
1 p.
artikel
592 P1.136 Recognition and prevalence of non motor symptoms of Parkinson's disease and their awareness; using non motor symptoms questionnaire Herekar, A.
2009
15 S2 p. S63-S64
2 p.
artikel
593 P3.124 Redox driven apoptotic signaling underlies 'selectivity vulnerability' in animal model of Parkinson's disease Karunakaran, S.
2009
15 S2 p. S180-
1 p.
artikel
594 P1.194 Reduced surround inhibition in professional musicians Shin, H.-W.
2009
15 S2 p. S79-
1 p.
artikel
595 P3.133 Regulation of movement energetic costs is impaired in basal ganglia disorders Moisello, C.
2009
15 S2 p. S182-
1 p.
artikel
596 P3.003 Regulation of neuronal alpha-synuclein gene expression by liver X receptor ligands Cheng, D.
2009
15 S2 p. S148-
1 p.
artikel
597 P2.176 Relation between subjective and objective measurements of activities of daily living in non-demented Parkinson's disease Díaz-Santos, M.
2009
15 S2 p. S137-S138
2 p.
artikel
598 P1.118 Relationship between olfactory dysfunction and Body Mass Index in patients with Parkinson disease Chou, K.
2009
15 S2 p. S59-
1 p.
artikel
599 P1.114 Relationship between the applause sign and neuropsychological proflle in patients with progressive supranuclear palsy (PSP) and Parkinson disease (PD) Tijero Merino, B.
2009
15 S2 p. S58-
1 p.
artikel
600 P2.187 Relationship of neighboring tissue and gliosis to a-synuclein pathology in a fetal graft to treat Parkinson disease Ahn, T.-B.
2009
15 S2 p. S140-
1 p.
artikel
601 P1.162 Relationship of neuromuscular strength to balance, functional mobility and quality of life in persons with Parkinson's disease Schilling, B.K.
2009
15 S2 p. S70-
1 p.
artikel
602 P1.106 Relationship of vascular lesions in the basal ganglia and white matter to parkinsonism Ahn, T.-B.
2009
15 S2 p. S56-
1 p.
artikel
603 P3.180 REM sleep behavior disorder in patients with Parkinson's disease and atypical parkinsonism Moscovich, M.
2009
15 S2 p. S194-
1 p.
artikel
604 P2.067 Resolving mode-of-inheritance and association of PRKN with PD in a comprehensive sequence and copy-number-variation (CNV) analysis of 3800 subjects Payami, H.
2009
15 S2 p. S106-S107
2 p.
artikel
605 P3.113 Rest energy expenditure in advanced Parkinson's disease: the impact of disease progression and drug treatment Ceravolo, M.G.
2009
15 S2 p. S177-
1 p.
artikel
606 P3.181 Restless Arms syndrome: report of 2 cases Munhoz, R.P.
2009
15 S2 p. S194-
1 p.
artikel
607 P3.184 Restless legs syndrome and depression in primary care patients Siemiński, M.
2009
15 S2 p. S195-
1 p.
artikel
608 P3.200 Restless legs syndrome in chronic renal failure patients under continuous ambulatory peritoneal dialysis Aksu, M.
2009
15 S2 p. S199-
1 p.
artikel
609 P3.185 Restless legs syndrome, sleep quality and interferon therapy in multiple sclerosis patients Siemiński, M.
2009
15 S2 p. S195-
1 p.
artikel
610 P1.012 Retrospective portrait of study recruitment success rate and identiflcation of barriers to participation in research using radiation Gavinio, J.
2009
15 S2 p. S31-S32
2 p.
artikel
611 P3.022 Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats Samad, N.
2009
15 S2 p. S153-
1 p.
artikel
612 P2.029 Reversing stimulation related cognitive-motor impairments in Parkinson's disease patients with a computational modeling approach to deep brain stimulation programming Frankemolle, A.M.M.
2009
15 S2 p. S96-
1 p.
artikel
613 P1.038 Rivastigmine treatment effects and the relationship between executive function and cognition, behavior and ADLs in Parkinson's disease dementia Schmitt, F.
2009
15 S2 p. S38-
1 p.
artikel
614 P3.050 Role of tumor necrosis factor in the progressive phase of dopaminergic neuron death in a rat model of Parkinson's disease Harms, A.
2009
15 S2 p. S161-
1 p.
artikel
615 P2.123 Ropinirole prolonged release improves nocturnal symptoms in patients with advanced Parkinson's disease: an analysis of grouped items on the PDSS Chaudhuri, K.R.
2009
15 S2 p. S122-S123
2 p.
artikel
616 P2.150 Ropinirole prolonged release improves nocturnal symptoms in patients with advanced Parkinson's disease: an analysis of individual items on the PDSS Ondo, W.
2009
15 S2 p. S130-
1 p.
artikel
617 P2.164 Ropinirole prolonged release maintains an increase in daily awake time spent “on” in patients with advanced Parkinson's disease Stocchi, F.
2009
15 S2 p. S134-
1 p.
artikel
618 P1.218 Safety, tolerability and pharmacokinetics of Cogane™ (PYM50028) studied over 28 days in healthy subjects and patients with mild-moderate Parkinson's disease Priestley, A.
2009
15 S2 p. S85-
1 p.
artikel
619 P2.098 Saflnamide as an adjunct to levodopa signiflcantly improved motor fluctuations in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study Borgohain, R.
2009
15 S2 p. S115-
1 p.
artikel
620 P2.048 Screening and selection process for deep brain stimulation: the Emory experience Revuelta, G.J.
2009
15 S2 p. S101-
1 p.
artikel
621 P3.006 Screening for E46K substitution in alpha-synuclein gene among familial parkinsonism in the Basque Country (Spain) yields negative results González-Fernández, M.C.
2009
15 S2 p. S149-
1 p.
artikel
622 P1.153 Secondary parkinsonism due to acquired hepatocerebral degeneration in an HIV patient with HCV liver cirrhosis, a case report Navarro-Fernández-Hidalgo, M.
2009
15 S2 p. S68-
1 p.
artikel
623 P1.096 Selective frontal atrophy of the inferior fronto-occipital fasciculus in progressive supranuclear palsy (PSP) Kvickström, P.
2009
15 S2 p. S53-
1 p.
artikel
624 P1.051 Selective inhibition of dopamine and noradrenaline transporters (DAT & NET) in the prefrontal cortex of COMT knock-out mice Käenmäki, M.
2009
15 S2 p. S42-
1 p.
artikel
625 P2.003 Selective spatial learning impairments and attention deflcits precede a frank motor phenotype in a mouse model of Parkinson's disease Browne, S.E.
2009
15 S2 p. S89-
1 p.
artikel
626 P2.184 Self-reported problems on visual activities of daily living in non-demented Parkinson's disease Seichepine, D.
2009
15 S2 p. S140-
1 p.
artikel
627 P1.157 Sensitivity to change of quality of life rating scales used in the PD MED trial Patel, S.
2009
15 S2 p. S69-
1 p.
artikel
628 P2.007 Serotonergic modulation of dopamine neurotransmission: a mechanism for extending therapeutics in schizophrenia Haleem, D.
2009
15 S2 p. S90-
1 p.
artikel
629 P3.103 Serum iron levels are lower in Parkinson's disease patients as compared to controls and are modifled by haptoglobin phenotype Costa-Mallen, P.
2009
15 S2 p. S174-
1 p.
artikel
630 P3.130 Serum proteomic biomarkers for the diagnosis of Parkinson's disease Markopoulou, K.
2009
15 S2 p. S181-
1 p.
artikel
631 P2.163 Short and long term beneflts of a community-based exercise program for people with Parkinson's disease Spierer, D.
2009
15 S2 p. S134-
1 p.
artikel
632 P1.014 Sialorrhea and salivary composition in patients with Parkinson's disease Yilmaz Kusbeci, O.
2009
15 S2 p. S32-
1 p.
artikel
633 P1.120 Side and type of motor symptoms at Parkinson's disease onset influence multiple motor and non-motor symptoms Baumann, C.
2009
15 S2 p. S59-S60
2 p.
artikel
634 P1.160 Signifacance of asymmetrical onset of symptoms in Parkinson's disease Pokharel, D.
2009
15 S2 p. S70-
1 p.
artikel
635 P3.118 Silencing/over-expressing selected genes as a novel model of sporadic Parkinson's disease Fishman-Jacob, T.
2009
15 S2 p. S178-
1 p.
artikel
636 P2.155 Simple overnight switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosage Rascol, O.
2009
15 S2 p. S131-S132
2 p.
artikel
637 P2.209 Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease Raisman Vozari, R.
2009
15 S2 p. S146-
1 p.
artikel
638 P3.013 Sirtuin inhibitors rescue synuclein toxicity: the natural inhibitor cicotinamide cured parkinsonism in pellagrins yet may be a Jekyll and Hyde Williams, A.C.
2009
15 S2 p. S151-
1 p.
artikel
639 P1.166 Sleep beneflt and quality of sleep in Parkinson's disease Stavitsky, K.
2009
15 S2 p. S71-
1 p.
artikel
640 P1.124 Sleep-disordered breathing in Parkinsonian disorders Cheon, S.-M.
2009
15 S2 p. S60-
1 p.
artikel
641 P3.075 Sleep disorders and disturbances in memory processing related to the lesion of the caudate nucleus Gogichadze, M.
2009
15 S2 p. S167-S168
2 p.
artikel
642 P3.172 Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model Barraud, Q.
2009
15 S2 p. S192-
1 p.
artikel
643 P3.177 Sleep-related falling out of bed (SFOB) in Parkinson's disease. A descriptive analysis Carvalho, D.
2009
15 S2 p. S193-S194
2 p.
artikel
644 P2.137 Somatodendritic serotonin-1A receptor responsiveness in the attenuation of apomorphine-induced sensitization by buspirone Ikram, H.
2009
15 S2 p. S126-
1 p.
artikel
645 P2.175 Sorafenib protects dopaminergic neurons from lipopolysaccharide-induced neurotoxicity via NF-úB inactivation Zhang, F.
2009
15 S2 p. S137-
1 p.
artikel
646 P1.025 SPAARS approach: integrated cognitive model of emotion of attention deflcit/hyperactivity disorder Khetrapal, N.
2009
15 S2 p. S35-
1 p.
artikel
647 P3.164 Specialized orthopedic rehabilitation promotes equivalent functional recovery in Parkinson's disease (PD) and non-neurological patients with hip fracture Frisina, P.
2009
15 S2 p. S190-
1 p.
artikel
648 P3.008 Spinal cord pathology in transgenic mice for Parkinson's disease Mendritzki, S.
2009
15 S2 p. S149-S150
2 p.
artikel
649 P1.095 Spinocerebellar ataxia 3 presenting as Parkinson disease – case series Mendonça, N.
2009
15 S2 p. S53-
1 p.
artikel
650 P1.079 Spinocerebellar ataxia types 3 and 10. Progression rate of gait ataxia in a group of 40 patients Helio, T.
2009
15 S2 p. S49-
1 p.
artikel
651 P3.109 State space mapping of sleep and wakefulness in Parkinson patients and healthy controls Sarnthein, J.
2009
15 S2 p. S176-
1 p.
artikel
652 P2.161 STEADY-PD: safety, tolerability, and efflcacy assessment of isradipine (Dynacirc CR) in early Parkinson disease Simuni, T.
2009
15 S2 p. S133-
1 p.
artikel
653 P1.117 Stereotypy following status epilepticus due herpetic encephalitis. Probable Kluver–Bucy syndrome Twardowschy, C.A.
2009
15 S2 p. S59-
1 p.
artikel
654 P1.178 Steroid-responsive post-traumatic dystonia: a video case report Hassan, A.
2009
15 S2 p. S74-S75
2 p.
artikel
655 P1.191 Stiff Person Syndrome as the initial manifestation of systemic lupus erythematosus – case report Munhoz, R.P.
2009
15 S2 p. S78-
1 p.
artikel
656 P2.196 STN high frequency stimulation is effective in Parkinson's disease with camptocormia: a case report Galazky, I.
2009
15 S2 p. S143-
1 p.
artikel
657 P1.052 Striatal catechol-O-methyltransferase after selective 6-OHDA lesions in the rat Schendzielorz, N.
2009
15 S2 p. S42-
1 p.
artikel
658 P3.079 Striatal muscarinic receptors facilitate frequency-sensitivity of striatal dopamine Pienaar, I.
2009
15 S2 p. S168-S169
2 p.
artikel
659 P3.060 Striatal oxidative stress proflle following partial dopaminergic depletion as assessed by a novel multifunctional marker molecule Aluf, Y.
2009
15 S2 p. S163-S164
2 p.
artikel
660 P1.223 Study of plantar pressure in Parkinson disease patients Chen, X.
2009
15 S2 p. S86-
1 p.
artikel
661 P1.085 Study on gait and balance in patients with Parkinson's disease Sandulescu, M.C.
2009
15 S2 p. S50-
1 p.
artikel
662 P2.075 Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage Wu, H.-M.
2009
15 S2 p. S109-
1 p.
artikel
663 P3.001 SUMOylation regulates a-synuclein toxicity Bähr, M.
2009
15 S2 p. S148-
1 p.
artikel
664 P3.093 Surgical series in G2019S and R1441G mutations of the LRRK2 gene in Parkinson's disease. DBS-coordinates and pallidotomy Echebarria Mendieta, S.G.
2009
15 S2 p. S172-
1 p.
artikel
665 P2.056 Survey of US neurologists' attitudes towards referral for deep brain stimulation for Parkinson's disease Shih, L.
2009
15 S2 p. S103-S104
2 p.
artikel
666 P3.141 Swift puriflcation of tyrosine hydroxylase from leaves of Mucuna prureins and its implication to gene therapy in Parkinson's disease Singh, S.
2009
15 S2 p. S184-
1 p.
artikel
667 P1.092 SWI sequence might be a diagnostic marker for PD and DLB Inoue, M.
2009
15 S2 p. S52-
1 p.
artikel
668 P2.093 Switch from subcutaneous apomorphine to intraduodenal levodopa offers additional beneflt on motor fluctuations and dyskinesias in advanced Parkinson's disease Tamburin, S.
2009
15 S2 p. S114-
1 p.
artikel
669 P2.116 Switching to ropinirole reduces the severity of daytime sleepiness associated with pramipexole therapy in Parkinson's disease with renal dysfunction Baba, Y.
2009
15 S2 p. S121-
1 p.
artikel
670 P1.112 Symmetric Parkinson's disease and atypical degenerative parkinsonism: common and differential aspects Moscovich, M.
2009
15 S2 p. S57-S58
2 p.
artikel
671 P3.142 Synaptic plasticity of corticostriatal and thalamostriatal systems in Parkinson's disease Smith, Y.
2009
15 S2 p. S184-
1 p.
artikel
672 P3.031 TaqI A polymorphism of dopamine D2 receptor gene (DRD2), dopamine dysregulation syndrome and impulse control disorders in Parkinson's disease Gorzkowska, A.
2009
15 S2 p. S156-
1 p.
artikel
673 P1.089 3T diffusion tensor MRI in differential diagnosis of Parkinson's disease and atypical parkinsonism Ferreiro Argüelles, C.
2009
15 S2 p. S51-S52
2 p.
artikel
674 P3.034 The analysis of LRRK 2 and parkin gene mutations in Slovakia Kracunova, K.
2009
15 S2 p. S156-S157
2 p.
artikel
675 P2.114 The changes in cortical excitability after rTMS in Parkinson disease are more pronounced on the side where the symptoms initiated Antczak, J.
2009
15 S2 p. S120-
1 p.
artikel
676 P1.035 The correlation on clinical characteristics between Parkinson disease with dementia and Alzheimer disease Ma, A.
2009
15 S2 p. S38-
1 p.
artikel
677 P3.036 The Cuban pathological CAG mutation causing SCA2 was introduced between 1408CE and 1733CE in the Cuban population Lafflta-Mesa, J.
2009
15 S2 p. S157-
1 p.
artikel
678 P2.105 The development of positive allosteric modulators of mGluR4 for the treatment of Parkinson's disease Niswender, C.
2009
15 S2 p. S117-
1 p.
artikel
679 P1.064 The effect of botulinum toxin type A on pain and sleep dysfunction related to cranio-cervical dystonia Metta, V.
2009
15 S2 p. S45-
1 p.
artikel
680 P3.171 The effect of high-volume walking with visual cues on gait in Parkinson's patients. A randomized controlled trial Sigurgeirsson, A.T.
2009
15 S2 p. S192-
1 p.
artikel
681 P1.200 The effect of mirtazapine on depression and tremor in essential tremor patients Telarovic, S.
2009
15 S2 p. S80-
1 p.
artikel
682 P2.135 The effect of subthalamic nucleus stimulation on nonmotor symptoms in Parkinson's disease Higuchi, M.-A.
2009
15 S2 p. S126-
1 p.
artikel
683 P2.160 The effects of a yoga program on Parkinson's disease Scott, M.
2009
15 S2 p. S133-
1 p.
artikel
684 P3.126 The effects of neuromelanin on a-synuclein over-expressed neuroblastoma cell line Li, J.
2009
15 S2 p. S180-
1 p.
artikel
685 P3.169 The efflcacy of a large-amplitude exercise approach for patients with Parkinson's disease Alvarez, M.
2009
15 S2 p. S191-
1 p.
artikel
686 P1.165 The epidemiology of Parkinson's disease in the Krasnodar Territory, Russia Sichinava, D.
2009
15 S2 p. S71-
1 p.
artikel
687 P2.027 The Harvard NeuroDiscovery Center Biomarker Study: accelerating biomarkers Scherzer, C.
2009
15 S2 p. S95-
1 p.
artikel
688 P1.032 The heterogeneous nature of Parkinson's dementia: a sub-cortical catecholamine subtype without Alzheimer's, Lewy body, or vascular pathology Frisina, P.
2009
15 S2 p. S37-
1 p.
artikel
689 P1.149 The ICF to classify activity and participation in Parkinson's disease Nickel, R.
2009
15 S2 p. S67-
1 p.
artikel
690 P2.188 The impact of donor age and environmental enrichment on functional recovery and dyskinesia in 6-OHDA lesioned rats Lane, E.
2009
15 S2 p. S141-
1 p.
artikel
691 P2.212 The impact of postural alterations and falls in the quality of life in patients with Parkinson's disease Maki, T.
2009
15 S2 p. S147-
1 p.
artikel
692 P2.084 The impact of switching to continuous release dopamine agonists on non-motor side effects Elmer, L.
2009
15 S2 p. S111-
1 p.
artikel
693 P1.037 The importance of oxidative stress in dementia progression Padurariu, M.
2009
15 S2 p. S38-
1 p.
artikel
694 P3.099 The influence of subcellular localization on LRRK2 LaVoie, M.J.
2009
15 S2 p. S173-S174
2 p.
artikel
695 P1.187 The Mayo Clinic functional movement disorders protocol: a symptom-based rehabilitation approach Czarnecki, K.
2009
15 S2 p. S77-
1 p.
artikel
696 P2.063 The multiple faces of Fahr calciflcations Ben Hamouda, I.
2009
15 S2 p. S105-
1 p.
artikel
697 P3.046 The MyD88 inflammatory pathway and its implication in a murine model of Parkinson's disease Drouin-Ouellet, J.
2009
15 S2 p. S160-
1 p.
artikel
698 P2.199 The national deep brain stimulation brain tissue network (DBS-BTN): preliminary results Vedam-Mai, V.
2009
15 S2 p. S143-S144
2 p.
artikel
699 P1.128 The natural history of treated PD: speech, gait and posture symptoms are a sensitive index of disease progression Evans, J.R.
2009
15 S2 p. S61-S62
2 p.
artikel
700 P3.069 The neurodegenerative process in the striatum develops in similar morphological patterns in both Huntington's disease patients and transgenic HD rats Mazurova, Y.
2009
15 S2 p. S166-
1 p.
artikel
701 P1.131 The Parkinson's disease Activities of Daily Living Scale (PADLS) revisited Hagell, P.
2009
15 S2 p. S62-
1 p.
artikel
702 P2.107 The protective effect of minocycline in 6-OHDA-induced toxicity in neuronal SH-SY5Y cells Ossola, B.
2009
15 S2 p. S118-
1 p.
artikel
703 P3.104 Therapeutic effect and probable mechanism of Rapamycin on MPTP-induced parkinsonism in mice Kangyong, L.
2009
15 S2 p. S174-S175
2 p.
artikel
704 P3.056 The relationship between blood levels of heavy metals and Parkinson's disease in China Tan, X.
2009
15 S2 p. S162-
1 p.
artikel
705 P2.066 Thermography method in Parkinson disease therapy clinical assessment Lukashevich, U.
2009
15 S2 p. S106-
1 p.
artikel
706 P2.087 The role of dopamine receptors in the induction of levodopa-induced dyskinesia in parkinsonsian rats Tsironis, C.
2009
15 S2 p. S112-
1 p.
artikel
707 P3.190 The role of early oxidative stress events in Parkinson's disease Hathaway, H.
2009
15 S2 p. S197-
1 p.
artikel
708 P3.196 The role of human photosynthesis in the understanding and treatment of Parkinson disease Areas-Esparza, M.D.C.
2009
15 S2 p. S198-
1 p.
artikel
709 P3.057 The roles of iron, Mn, zinc on the PD development? Relationship between food intake and serum concentrations Tan, X.
2009
15 S2 p. S163-
1 p.
artikel
710 P1.177 The school for patients with Parkinson's disease Zhukova, I.
2009
15 S2 p. S74-
1 p.
artikel
711 P2.185 The social intervention for people with Parkinson disease in Transylvania region Stoica, L.
2009
15 S2 p. S140-
1 p.
artikel
712 P3.063 The unique properties of 9-methyl-b-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects Polanski, W.
2009
15 S2 p. S164-
1 p.
artikel
713 P1.009 The utilization of a caregiver questionnaire in an outpatient movement disorder clinic to examine and address caregiver distress Book, E.
2009
15 S2 p. S31-
1 p.
artikel
714 P2.061 The value of MRI in the early disease stages of parkinsonian disorders: a prospective three year follow-up study Abdo, W.
2009
15 S2 p. S105-
1 p.
artikel
715 P1.228 The values of electromyography as a surrogate for the clinical diagnosis of the essential tremor Jeong, D.
2009
15 S2 p. S87-S88
2 p.
artikel
716 P3.073 Time-frequency and spectral analysis of auditory executive event-related potentials from subthalamic nucleus Baláž, M.
2009
15 S2 p. S167-
1 p.
artikel
717 P2.181 Time geography and quality of life for persons with Parkinson's disease Mcnulty, T.
2009
15 S2 p. S139-
1 p.
artikel
718 P1.093 3T MR siderotractography characteristics in Parkinson's disease and atypical Parkinson plus syndromes Kandadai, R.M.
2009
15 S2 p. S52-S53
2 p.
artikel
719 P1.167 Tongue bradykinesia is related to severity of drooling in Parkinson's disease Tsuboi, Y.
2009
15 S2 p. S71-S72
2 p.
artikel
720 P1.132 Towards an evidence base for selecting rating scale response categories for patient-reported outcome measures in Parkinson's disease Knutsson, I.
2009
15 S2 p. S62-S63
2 p.
artikel
721 P3.084 Toxic influence on Parkinson disease: 5 years follow-up study Budisic, M.
2009
15 S2 p. S170-
1 p.
artikel
722 P1.219 Traditional Chinese medicine improves activities of daily living in Parkinson's disease Weidong, P.
2009
15 S2 p. S85-
1 p.
artikel
723 P2.024 Transcranial sonography in Parkinson's disease: diagnostic and prognostic application Fedotova, E.Y.
2009
15 S2 p. S94-
1 p.
artikel
724 P1.087 Transcranial sonography (TCS) in evaluation of patients with essential tremor (ET) Crnjakovic, M.
2009
15 S2 p. S51-
1 p.
artikel
725 P2.171 Transdermal lisuride achieves stable plasma levels in Parkinson's disease (PD) Vacca, L.
2009
15 S2 p. S136-
1 p.
artikel
726 P3.175 Transdermal lisuride is effective in Restless Legs Syndrome (RLS) Beneŝs, H.
2009
15 S2 p. S193-
1 p.
artikel
727 P2.009 Transduction of cells in the subventricular zone with adenoviruses cleaned and concentrated by using membrane chromatograpy Hildebrandt, S.
2009
15 S2 p. S90-
1 p.
artikel
728 P2.129 Transplant of autologous bone marrow stem cells into Parkinson's disease patients is safe and may improve their quality of life Geffner, L.
2009
15 S2 p. S124-
1 p.
artikel
729 P3.121 Trauma and Parkinson's disease: some observations Jha, S.
2009
15 S2 p. S179-
1 p.
artikel
730 P2.169 Treatment of advanced Parkinson's disease in the United States: a cost-utility model Tarrants, M.
2009
15 S2 p. S135-S136
2 p.
artikel
731 P1.017 Treatment of chorea in Huntington disease with oral non-ergot dopamine agonists Gunzler, S.
2009
15 S2 p. S33-
1 p.
artikel
732 P2.147 Treatment of patients with early and advanced Parkinson's disease with transdermal rotigotine: safety and tolerability in elderly patients Oertel, W.
2009
15 S2 p. S129-
1 p.
artikel
733 P1.084 Two cases of cerebellar ataxia associated with Hashimoto's encephalopathy Park, H.D.
2009
15 S2 p. S50-
1 p.
artikel
734 P2.193 Tyramine leak to urine. A clue for early detection of idiopathic parkinsonians Ómez, L.M.G.
2009
15 S2 p. S142-
1 p.
artikel
735 P1.214 Uncertainty vs. likelihood of reward: implications for the placebo effect in Parkinson's disease Srinivasan, J.
2009
15 S2 p. S84-
1 p.
artikel
736 P3.120 Uncontrolled neuroinflammation drives progressive neurodegeneration in Parkinson's disease Gao, H.-M.
2009
15 S2 p. S179-
1 p.
artikel
737 P1.116 Underlying causes of pathologic hiccup Ha, C.K.
2009
15 S2 p. S58-S59
2 p.
artikel
738 P1.220 Unilateral deep brain stimulation in Parkinson disease improves ipsilateral symptoms regardless of laterality Shemisa, K.
2009
15 S2 p. S86-
1 p.
artikel
739 P3.053 Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent Jiang, H.
2009
15 S2 p. S162-
1 p.
artikel
740 P2.078 Usage and cost of complementary therapies in hemifacial spasm Ratnagopal, P.
2009
15 S2 p. S109-S110
2 p.
artikel
741 P2.208 Using error to evaluate basal ganglia contributions to timing control during gait in Parkinson's disease Almeida, Q.J.
2009
15 S2 p. S146-
1 p.
artikel
742 P1.173 Validation of a home environment test battery for status assessment in patients with advanced Parkinson's disease Westin, J.
2009
15 S2 p. S73-
1 p.
artikel
743 P1.024 Verbal fluency and psychomotor speed in early Parkinson's disease: is there a link? Hipp, G.
2009
15 S2 p. S35-
1 p.
artikel
744 P1.207 Visual related cognitive assessments in Parkinson disease and MCI patients Li, Y.
2009
15 S2 p. S82-
1 p.
artikel
745 P2.156 Wearing-off management in Parkinson's disease: the LEVOSTAR study two-year optional follow-up Houeto, J.-L.
2009
15 S2 p. S132-
1 p.
artikel
746 P2.117 Wearing-off symptoms in Parkinson's disease patients on L-DOPA in the Czech Republic – the results of E.W.O. study Bares, M.
2009
15 S2 p. S121-
1 p.
artikel
747 P2.051 Weight gain in Parkinson's disease following STN DBS is related to the medial position of active electrode contact in subthalamus Ruzicka, F.
2009
15 S2 p. S102-
1 p.
artikel
748 P3.055 Welding fume-related dopaminergic neurotoxicity Sriram, K.
2009
15 S2 p. S162-
1 p.
artikel
749 P1.048 WHO-5 Well-being Index as a screening instrument for Parkinson's disease patients with major depression (ICD-10) Storch, A.
2009
15 S2 p. S41-
1 p.
artikel
750 P1.201 Wilson disease in young adolescent with hepatitis C – case report Boshkovski, B.
2009
15 S2 p. S80-S81
2 p.
artikel
751 P1.185 Worry in Parkinson's disease: baseline data from the PROMS-PD cohort Whitehead, D.
2009
15 S2 p. S76-
1 p.
artikel
752 P2.099 Zonisamide as an adjunctive therapy in idiopathic Parkinson's disease Borgohain, R.
2009
15 S2 p. S115-
1 p.
artikel
                             752 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland